<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Rep</journal-id><journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id><journal-title-group><journal-title>Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2211-1247</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39964812</article-id><article-id pub-id-type="pmc">PMC11861568</article-id><article-id pub-id-type="pii">S2211-1247(25)00090-7</article-id><article-id pub-id-type="doi">10.1016/j.celrep.2025.115319</article-id><article-id pub-id-type="publisher-id">115319</article-id><article-categories><subj-group subj-group-type="heading"><subject>Resource</subject></subj-group></article-categories><title-group><article-title>Luminescent sensing of conformational integrin activation in living cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Villari</surname><given-names>Giulia</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Gioelli</surname><given-names>Noemi</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Gino</surname><given-names>Marta</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Zhang</surname><given-names>Heng</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Hodge</surname><given-names>Kelly</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Cordero</surname><given-names>Francesca</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Zanivan</surname><given-names>Sara</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Zhu</surname><given-names>Jieqing</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Serini</surname><given-names>Guido</given-names></name><email>guido.serini@ircc.it</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">8</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Department of Oncology, University of Torino School of Medicine, Candiolo, TO, Italy</aff><aff id="aff2"><label>2</label>Candiolo Cancer Institute - Fondazione del Piemonte per l&#x02019;Oncologia (FPO) Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, TO, Italy</aff><aff id="aff3"><label>3</label>Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI, USA</aff><aff id="aff4"><label>4</label>Cancer Research UK Scotland Institute, Glasgow, UK</aff><aff id="aff5"><label>5</label>Department of Computer Science, University of Torino, Torino, Italy</aff><aff id="aff6"><label>6</label>School of Cancer Sciences, University of Glasgow, Glasgow, UK</aff><aff id="aff7"><label>7</label>Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>guido.serini@ircc.it</email></corresp><fn id="fn1"><label>8</label><p id="ntpara0010">Lead contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>17</day><month>2</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><volume>44</volume><issue>2</issue><elocation-id>115319</elocation-id><history><date date-type="received"><day>14</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>29</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Integrins are major receptors for secreted extracellular matrix, playing crucial roles in physiological and pathological contexts, such as angiogenesis and cancer. Regulation of the transition between inactive and active conformation is key for integrins to fulfill their functions, and pharmacological control of those dynamics may have therapeutic applications. We create and validate a prototypic luminescent &#x003b2;1 integrin activation sensor (&#x003b2;1IAS) by introducing a split luciferase into an activation reporting site between the &#x003b2;I and the hybrid domains. As a recombinant protein in both solution and living cells, &#x003b2;1IAS accurately reports &#x003b2;1 integrin activation in response to (bio)chemical and physical stimuli. A short interfering RNA (siRNA) high-throughput screening on live &#x003b2;1IAS knockin endothelial cells unveils hitherto unknown regulators of &#x003b2;1 integrin activation, such as &#x003b2;1 integrin inhibitors E3 ligase Pja2 and vascular endothelial growth factor B (VEGF-B). This split-luciferase-based strategy provides an <italic>in situ</italic> label-free measurement of integrin activation and may be applicable to other &#x003b2; integrins and receptors.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">&#x003b2;1IAS reports &#x003b2;1 integrin activation in response to biochemical and physical stimuli</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">siRNA HTS on &#x003b2;1IAS KI endothelial cells unveils unknown regulators of &#x003b2;1 integrin activation</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">E3 ubiquitin ligase Pja2 promotes kindlin-2 degradation and inhibits &#x003b2;1 integrin activation</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">VEGF-B is a so far unrecognized effective inhibitor of &#x003b2;1 integrin activation</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>Villari et&#x000a0;al. present the generation of a luminescent reporter for a &#x003b2;1 integrin activation sensor (&#x003b2;1IAS). A siRNA HTS on &#x003b2;1IAS KI endothelial cells revealed previously uncharacterized regulators of &#x003b2;1 integrin activation: the E3 ubiquitin ligase Pja2, which promotes kindlin-2 degradation, and the VEGF-B, which stabilizes &#x003b2;1 integrin inactive conformation.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>integrin activation</kwd><kwd>luminescence</kwd><kwd>conformational sensor</kwd><kwd>integrin inhibitors</kwd><kwd>endothelial cells</kwd><kwd>angiogenesis</kwd></kwd-group></article-meta><notes><p id="misc9010">Published: February 17, 2025</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Integrins are the main adhesion receptors through which cells of metazoans physically connect their actin cytoskeleton to polymeric extracellular matrix (ECM) ligands.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> These heterodimeric &#x003b1;&#x003b2; transmembrane receptors control essential physiological functions, such as organogenesis,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> angiogenesis,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> neuronal connectivity,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> platelet aggregation,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> and leukocyte extravasation.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> On the other hand, alterations in integrin-mediated adhesion are involved in the pathogenesis of several diseases, such as coagulopathies,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref> immune disorders,<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> and cancer.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> The core of the regulation of integrin adhesive functions lies in the spatiotemporal modulation of their large-scale conformational changes within the extracellular domains composed of headpiece and leg portions.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> On the cell surface, integrins exist in a dynamic equilibrium between inactive (bent-closed and low-affinity) and active (extended-open and high-affinity) conformations,<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> which is regulated by signal transduction pathways that may have been incompletely discovered and whose targeting may provide opportunities for therapeutic intervention.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Thus, it is crucial to devise methods that allow a simple, quantitative, and noninvasive measurement of integrin conformational states in live cells and may be exploited in high-throughput screenings (HTSs) to identify until-now unnoticed ligands, receptors, biochemical signaling pathways, or drugs capable of inhibiting or activating integrin function. Here, we describe the development of a bioorthogonal luminescent sensor that, when knocked in at a critical position within the human &#x003b2;1 integrin gene (<italic>ITGB1</italic>), allows a quantitative measurement of the conformational transition happening during &#x003b2;1 integrin activation in living vascular endothelial cells (ECs) and the identification of so far unrecognized &#x003b2;1 integrin regulators by means of a short interfering RNA (siRNA) HTS.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Design and characterization of a luminescent &#x003b2;1 integrin activation sensor in living cells</title><p id="p0035">In inactive integrins, the &#x003b1; and &#x003b2; subunits are tightly associated along their whole length, and the extracellular N-terminal headpiece, which displays a closed, low-affinity conformation, is bent over the plasma membrane proximal leg.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> In active integrins, while the headpiece moves away from the leg, adopting an open, high-affinity conformation, the fully extended &#x003b1; and &#x003b2; subunits separate, remaining in contact only at the ligand binding site.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Following the split of the two subunits, the cytosolic domain of the &#x003b2; chain is then free to associate with the talin and kindlin adaptors that connect integrins to the actin cytoskeleton, thus enabling ECM adhesion.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="p0040">Endothelial &#x003b2;1 integrins are required for physiological angiogenesis both in the embryo<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> and postnatally.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> Furthermore, the regulation of the conformational activation of endothelial &#x003b2;1 integrins is crucial for the formation of functional vascular networks<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="bib17" ref-type="bibr"><sup>17</sup></xref> and pathologically increased in abnormal cancer blood vessels.<xref rid="bib18" ref-type="bibr"><sup>18</sup></xref> The identification of signaling pathways controlling &#x003b2;1 integrin conformational activation in ECs may support the design of vascular normalization strategies for cancer therapy.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> Hence, we sought to rationally design and generate a biochemical sensor capable of perceiving the conformational activation of endothelial &#x003b2;1 integrins and then exploit it in siRNA HTSs. We identified a functionally critical positional change within the &#x003b2;1 integrin extracellular domain that, without altering the receptor adhesive capacity, may be coupled to and revealed by a reversible and effective enzymatic system. In this regard, the key conformational transition connecting the headpiece opening and the separation of the &#x003b1; and &#x003b2; subunits happening during integrin activation strictly depends on the about 60&#x000b0; oscillation through which the hybrid domain moves away and aligns with the &#x003b2;I domain.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Thus, we chose to insert a reversibly activatable enzyme tag into the externally exposed S<sub>79</sub>-K<sub>85</sub> loop (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A) that shifts coordinately with the outward swinging hybrid domain during &#x003b2;1 integrin activation.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> Short Myc and hemagglutinin (HA) tags have already been successfully inserted into the long serine-rich stretch that is present in this loop in <italic>Drosophila</italic> &#x003b2;PS integrins only.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Moreover, 27&#x02013;33&#x000a0;kDa tags were already inserted in the S<sub>79</sub>-K<sub>85</sub> loop<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> or in its vicinity<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> without affecting the functional properties of &#x003b2;1 integrins. We selected the Promega NanoLuc Binary Technology (NanoBiT) split luciferase formed by a large (LgBiT) and a small (SmBiT) subunit as an enzymatic tag, which has an extremely low self-association affinity but is able to reconstitute the catalytically active NanoBiT luciferase enzyme and brightly luminesce when brought into close proximity<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). We designed the luminescent &#x003b2;1 integrin activation sensor (&#x003b2;1IAS) by inserting the LgBiT and SmBiT subunits of the NanoBiT, separated by a 15-amino-acid-long Gly-Ser linker, into the S<sub>79</sub>-K<sub>85</sub> loop of human &#x003b2;1 integrins (<xref rid="fig1" ref-type="fig">Figures&#x000a0;1</xref>A and 1B), aiming to reconstitute the NanoBiT luciferase enzymatic activity during the hybrid domain swing-out movement (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>B). We first created a soluble C-terminally clasped extracellular portion of &#x003b1;5&#x003b2;1IAS, which promotes secretion and the inactive bent/closed conformation,<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> detected by both &#x003b1;5 and &#x003b2;1 integrin antibodies (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). To this end, we added to the C-terminal end of the &#x003b1;5 and &#x003b2;1IAS subunit an amino acid linker containing a tobacco etch virus (TEV) protease site and an acidic or basic peptide, respectively, which, by heterodimerizing and forming a disulfide bridge, give rise to a clasped coiled-coil structure<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C). On the other hand, digestion with TEV protease allowed the generation of a soluble unclasped extracellular portion of &#x003b1;5&#x003b2;1IAS (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C), known to favor the active extended/open conformation.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Then, we measured the extent of luminescence emitted by equal amounts of the clasped or unclasped extracellular portion of &#x003b1;5&#x003b2;1IAS exposed to immobilized bovine serum albumin (BSA) or fibronectin (FN) in the presence of physiological (1&#x000a0;mM Ca<sup>2+</sup> or 1&#x000a0;mM Mg<sup>2+</sup>) or activating (2&#x000a0;mM Mn<sup>2+</sup>) concentrations of metal ions (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). We observed that under control conditions and in the presence of BSA, the unclasped extracellular portion of &#x003b1;5&#x003b2;1IAS emitted a higher amount of luminescence than its clasped counterpart (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). In addition, the contact with the FN ligand stimulated a marked increase in the luminescent signal emitted by the extracellular portion of both clasped and unclasped &#x003b1;5&#x003b2;1IASs in the presence of physiological or activating concentrations of metal ions (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). Thus, the recombinant extracellular portion of &#x003b2;1IAS behaves as an effective and reliable reporter of the &#x003b2;1 integrin conformational activation state.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Design and validation of &#x003b2;1IAS purified extracellular protein</p><p>(A) Diagram of &#x003b2;1 integrin activation sensor (&#x003b2;1IAS) construct. Created with <ext-link ext-link-type="uri" xlink:href="http://BioRender.com" id="intref0070">BioRender.com</ext-link>.</p><p>(B) Molecular modeling of NanoBiT activity reconstruction in &#x003b1;5&#x003b2;1IAS during hybrid domain swing-out and headpiece opening. The headpiece structures of &#x003b2;1 integrin in closed and open conformations were modeled from PDB: <ext-link ext-link-type="PDB" xlink:href="https://www.rcsb.org/7CEB" id="intref0075">7CEB</ext-link> and <ext-link ext-link-type="PDB" xlink:href="https://www.rcsb.org/7CEB" id="intref0080">7CEB</ext-link>. The structure of NanoBiT was modeled from PDB: <ext-link ext-link-type="PDB" xlink:href="https://www.rcsb.org/7SNX" id="intref0085">7SNX</ext-link>.</p><p>(C) The ectodomains of &#x003b1;5&#x003b2;1 WT and &#x003b1;5&#x003b2;1IAS were expressed with a C-terminal disulfide-linked ACID-BASE coiled coil in Expi293F or HEK293 cells. The presence of purified soluble proteins was detected by western blot using anti-&#x003b1;5 (A11) and anti-&#x003b2;1 (TS2/16) in non-reducing conditions.</p><p>(D) Luminescence of purified ectodomain of &#x003b1;5&#x003b2;1IAS with (clasped) or without (unclasped) the ACID-BASE coiled coil and in the absence (CTL) or presence of immobilized BSA or fibronectin (FN) under resting (Ca<sup>2+</sup>) or activating (Mn<sup>2+</sup>) metal ion conditions. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0045">Then, we retrovirally transduced the cDNA construct encoding for human &#x003b2;1IAS into &#x003b2;1 integrin-knockout mouse embryonic fibroblasts<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs), comparing it with human wild-type &#x003b2;1 integrin (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1WT MEFs), and verified its surface exposure by fluorescence flow cytometry (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A). Moreover, as assessed by electric impedance sensing, &#x003b2;1IAS transduction effectively rescued the capability of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs to adhere to the main &#x003b1;5&#x003b2;1 integrin ligand FN (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B). In addition, confocal microscopy showed that transduced &#x003b2;1IAS physiologically localizes in vinculin containing ECM adhesions of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>C). Notably, with luminescent microscopy, we detected photon signals specifically emanating from <italic>bona fide</italic> ECM adhesions of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs, but not <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs, retrovirally transduced with intact NanoLuc (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc MEFs) plated on FN (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>D). To directly evaluate the ability of &#x003b2;1IAS to report the conformational activation of &#x003b2;1 integrins as a luminescence sensor, we challenged <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs with activating stimuli and employed <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc MEFs as a negative control. We observed that plating the same number of cells on increasing amounts of FN for 1&#x000a0;h resulted in a proportional rise in the luminescence of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs but not control <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc MEFs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E). Analogously, we detected an augmenting luminescent signal when <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs, but not <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc MEFs, were grown on increasing stiffness hydrogels (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>F). Therefore, functionally behaving as a WT &#x003b2;1 integrin, &#x003b2;1IAS represents an unprecedented luminescent sensor that allows noninvasive and quantitative measurements of &#x003b2;1 integrin conformational activation in living cells.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>&#x003b2;1IAS functional characterization in <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs</p><p>(A) Top: western blot showing the expression of &#x003b2;1 integrin and NanoBiT in &#x003b2;1 integrin-null (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>) mouse embryonic fibroblasts (MEFs) transduced with retroviral vector pLZRS-human WT &#x003b2;1 integrin (&#x003b2;1WT) or -&#x003b2;1IAS. Bottom: fluorescence-activated cell sorting (FACS) analysis using 9EG7 antibody in WT MEFs, <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>, and <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> transduced with &#x003b2;1IAS (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS).</p><p>(B) Relative adhesion measured by the xCELLigence system in WT, <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>, and <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs plated on FN. Data are the mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(C) Confocal microscopy showing vinculin (green) and 9EG7<sup>+</sup> active &#x003b2;1 integrins (red) in WT, <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>, and <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs plated on FN. The left image insets highlight focal adhesion sites. Scale bar: 20&#x000a0;&#x003bc;m.</p><p>(D) Luminescent microscopy in the presence of furimazine of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs transfected with either intact NanoLuc (left) or &#x003b2;1IAS (right) and plated on FN. Image insets show how most photons generated by &#x003b2;1IAS localize into <italic>bona fide</italic> focal adhesion sites (right) compared to the random localization of intact NanoLuc (left). Low-magnification (left) scale bars: 20&#x000a0;&#x003bc;m; high-magnification (right) scale bars: 5&#x000a0;&#x003bc;m.</p><p>(E) Luminescence of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs adhering for 30&#x000a0;min to increasing amounts (125&#x02013;1,000&#x000a0;ng/mL) of FN compared to <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs transfected with intact NanoLuc (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc). Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(F) Luminescence of <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs adhering for 30&#x000a0;min to FN-coated, increasingly stiff (0.5, 10, and 100&#x000a0;kPa) PAGEs compared to <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs transfected with intact NanoLuc (<italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/NanoLuc). Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="p0050">Next, to chart signaling pathways responsible for the dynamic tuning of &#x003b2;1 integrin conformational activation in living human ECs, we generated heterozygous knockin (KI) immortalized primary ECs (TeloHAECs) stably expressing &#x003b2;1IAS (&#x003b2;1IAS KI ECs). Using the CRISPR-Cas9 system, we inserted a construct encoding for NanoBiT LgBiT and SmBiT subunits, separated by a 15-amino-acid-long Gly-Ser linker, into the S<sub>79</sub>-K<sub>85</sub> loop (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A), encoded by exon 4, of the human &#x003b2;1 integrin (<italic>ITGB1</italic>) gene of parental WT TeloHAECs and isolated a &#x003b2;1IAS KI EC clone (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A). The NanoLuc antibody revealed that the NanoBiT/Gly-Ser linker insertion (&#x02248;20&#x000a0;kDa) was integrated in both the precursor (transforming it from 110 to 130&#x000a0;kDa) and mature (transforming it from 130 to 150&#x000a0;kDa) forms of &#x003b2;1 integrin. The three bands (of 110, 130, and 150&#x000a0;kDa) detected by the &#x003b2;1 integrin antibody in the &#x003b2;1IAS KI EC clone (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A) confirmed the heterozygosity of the clonal cell population. As its WT counterpart, the &#x003b2;1IAS subunit effectively dimerized with integrin &#x003b1; subunits, e.g., &#x003b1;2, &#x003b1;5, and &#x003b1;v (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>). &#x003b2;1IAS KI ECs adhered to FN over time as WT TeloHAECs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). As observed with <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>E), we detected a proportionally growing luminescent signal when &#x003b2;1IAS KI ECs were allowed to adhere for 30&#x000a0;min to increasing concentrations of FN (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C, white). We also detected a proportionally growing luminescent signal when &#x003b2;1IAS KI ECs were allowed to adhere for 30&#x000a0;min on increasing concentrations of type I collagen (Coll I) (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C, black) and laminin 511 (Lam 511)<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C, gray), which are the main ligands of &#x003b1;2&#x003b2;1 and &#x003b1;6&#x003b2;1 integrins, respectively, thus supporting the exploitability of &#x003b2;1IAS in revealing the conformational activation of other &#x003b2;1 integrin dimers than the FN receptor &#x003b1;5&#x003b2;1 integrin in human ECs. We did not detect a luminescent signal when &#x003b2;1IAS KI ECs were allowed to adhere for 30&#x000a0;min to increasing concentrations of vitronectin (VN) (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>D), the main ECM ligand of &#x003b1;v&#x003b2;5 and &#x003b1;v&#x003b2;3 integrins, thus supporting the specificity of &#x003b2;1IAS in revealing &#x003b2;1 integrin activation only in human ECs. To further characterize the specificity of &#x003b2;1IAS in detecting integrin-dependent adhesion, we plated &#x003b2;1IAS KI ECs for 30&#x000a0;min on poly-D-lysine (1&#x000a0;mg/mL) and did not detect a background luminescent signal, compared to FN (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S2</xref>). Like <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup>/&#x003b2;1IAS MEFs (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>F), when grown on hydrogels with increasing stiffness, &#x003b2;1IAS KI ECs also emitted proportionally rising luminescence (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>E). To further functionally characterize &#x003b2;1IAS KI ECs, we took advantage of 9EG7<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> and 12G10<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> monoclonal antibodies (mAbs) that specifically recognize and stabilize the active conformation of &#x003b2;1 integrins. To maximize the capability of detecting a positive modulation of &#x003b2;1 integrin activation, the cells were allowed to adhere to the same amount of FN for 15&#x000a0;min, in the presence or absence of the two mAbs. Of note, we documented how &#x003b2;1 integrin-activating mAbs significantly increase the luminescent signal emitted by &#x003b2;1IAS KI ECs adhering to FN (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>F). In contrast, to evaluate the exploitability &#x003b2;1IAS to detect &#x003b2;1 integrins in their inactive state, we used mAb13, which specifically recognizes and stabilizes the inactive conformation,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> and the inhibitor MK-0429, which behaves as a potent pan-&#x003b1;v integrin and &#x003b1;5&#x003b2;1 integrin antagonist.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> We let &#x003b2;1IAS KI ECs adhere to the same amount of FN for 15&#x000a0;min, in the presence or absence of mAb13 or MK-0429. Both inhibiting stimuli significantly decreased the extent of luminescent signal emitted by &#x003b2;1IAS KI ECs adhering to FN (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>G). Furthermore, we observed that siRNA-mediated silencing of well-known activators of integrin function, such as talin-1 (TLN1), kindlin-2 (FERMT2), and kindlin-3 (FERMT3) adaptor proteins<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>A), results in a significant drop of the luminescent signal of &#x003b2;1IAS KI ECs allowed to adhere to FN for 1 h, compared to &#x003b2;1IAS KI ECs silenced with control siRNA (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>H), without affecting cell viability (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B). The silencing of FN leucine-rich transmembrane protein 2 (FLRT2) ligand<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> or its receptor latrophilin 2 (LPHN2)<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> or the semaphorin receptor plexin D1 (PLXND1),<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> which we<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> and others<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> found to inhibit, via different mechanisms, the function of the major integrin activating small GTPase Rap1,<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> caused instead a robust elevation of &#x003b2;1IAS KI EC luminescence (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>I), without affecting cell viability (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B). Those data substantiate the successful generation of an EC clone constitutively expressing an effective sensor of the conformational activation state of &#x003b2;1 integrin and its potential exploitability in HTSs to identify signaling pathways or drugs capable of positively or negatively modulating &#x003b2;1 integrin activation and function in living ECs.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>&#x003b2;1IAS functional characterization in genetic &#x003b2;1IAS KI TeloHAECs</p><p>(A) Western blot showing the expression of &#x003b2;1 integrin and NanoBiT tag in &#x003b2;1IAS knockin (KI) ECs compared to WT TeloHAECs (parental).</p><p>(B) Relative adhesion measured by the xCELLigence system in &#x003b2;1IAS KI ECs plated on FN compared to parental ECs. Data are the mean&#x000a0;&#x000b1; SD of four independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(C) Luminescence of &#x003b2;1IAS KI ECs adhering for 30&#x000a0;min to increasing amounts (125&#x02013;1,000&#x000a0;ng/mL) of FN, collagen type I (Coll I), or laminin 511 (Lam 511). Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(D) Luminescence of &#x003b2;1IAS KI ECs adhering for 30&#x000a0;min to increasing amounts (125&#x02013;1,000&#x000a0;ng/mL) of vitronectin (VN). Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(E) Luminescence of &#x003b2;1IAS KI ECs adhering for 30&#x000a0;min to FN-coated, increasingly stiff (10 and 100&#x000a0;kPa) PAGEs. Data are mean&#x000a0;&#x000b1; SD of four independent experiments. Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t-test.</p><p>(F) Luminescence of &#x003b2;1IAS KI ECs adhering for 15&#x000a0;min to 500&#x000a0;ng/mL FN in the presence of 9EG7 and 12G10 antibodies. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(G) Luminescence of &#x003b2;1IAS KI ECs adhering for 15&#x000a0;min to 500&#x000a0;ng/mL FN in the presence of mAb13 or the pan-&#x003b1;v integrin and &#x003b1;5&#x003b2;1 antagonist MK-0429 (100&#x000a0;&#x003bc;M). Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(H) Luminescence of control &#x003b2;1IAS KI ECs (siCTL) and &#x003b2;1IAS KI ECs silenced for TLN1, FERMT2, and FERMT3 and then plated on 500&#x000a0;ng/mL FN. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(I) Luminescence of control &#x003b2;1IAS KI ECs (siCTL) and &#x003b2;1IAS KI ECs silenced for FLRT2, LPHN2, and PLXND1 and then plated on 500&#x000a0;ng/mL FN. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.2"><title>Identification of key molecular pathways controlling &#x003b2;1 integrin activation in ECs</title><p id="p0055">To assess whether and how the scaling and proportional emission of luminescence by &#x003b2;1IAS KI ECs may be exploited to pinpoint previously uncharacterized regulators of endothelial &#x003b2;1 integrin conformational activation, we conducted a luminescent siRNA HTS using a human Druggable Genome v.3 siRNA library. RNA sequencing (RNA-seq) analysis filtered 3,978 out of 6,948 druggable genome library siRNAs, whose mRNAs were not actively transcribed in &#x003b2;1IAS KI ECs. In the HTS, 2,970 expressed genes were silenced in &#x003b2;1IAS KI ECs, and the resulting luminescence emission data were measured and analyzed, unveiling 194 statistically significantly candidate genes that emerged as positive (142 genes, <italic>Z</italic> score&#x000a0;&#x0003c;&#x000a0;&#x02212;2) or negative (52 genes, <italic>Z</italic> score &#x0003e;2) regulators of &#x003b2;1 integrin activation (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>A). Bioinformatic analysis of candidate genes, performed through an EnrichR web-based tool used to combine KEGG, WikiPathway, NCI-Nature, and BioPlanet databases, identified as top enriched pathways those governing integrin-based focal adhesion formation and signaling, along with vascular endothelial growth factor (VEGF) signaling, axon guidance, and integrin cell surface interactions and signaling (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S4</xref>; <xref rid="mmc3" ref-type="supplementary-material">Table&#x000a0;S2</xref>). In addition to ITGB1 itself, among &#x003b2;1IAS positive regulators, we identified genes encoding for proteins known to promote (1) &#x003b2;1 integrin conformational activation, e.g., the talin activating small GTPase RAP1B,<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> the &#x003b2;1 integrin adaptor tensin 3 (TNS3),<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> the reported &#x003b2;2 integrin activator cathepsin K (CTSK),<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> and the &#x003b1;5&#x003b2;1 integrin ligand&#x000a0;tubulointerstitial nephritis antigen-like 1 (TINAGL1)<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>; (2)&#x000a0;&#x003b2;1 integrin endosomal recycling, e.g., sorting nexin 17 (SNX17<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>), RAS p21 protein activator 1&#x000a0;(RASA1, also known as [aka] p120RASGAP),<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and RAB1A<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref>; (3) focal adhesion formation, e.g., RHOJ,<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> BCAR1 scaffold protein, Cas family member (BCAR1, aka p130Cas),<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> and the BCAR1/p130Cas interactor CASP8 and FADD-like apoptosis regulator (CFLAR)<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>; and (4) angiogenesis, e.g., fibroblast growth factor receptor 1&#x000a0;(FGFR1),<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> angiogenin (ANG),<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and semaphorin 4D (SEMA4D)<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> and its receptor PLXNB1,<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> which we previously showed to promote blood vessel formation by recruiting the MET tyrosine kinase receptor<xref rid="bib57" ref-type="bibr"><sup>57</sup></xref> (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). On the other hand, beyond the few already described negative regulators of &#x003b2;1 integrin activation and function, such as urokinase plasminogen activator receptor (PLAUR, aka uPAR)<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> and Rac GTPase-activating protein 1 (RACGAP1),<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> we pinpointed several hitherto unknown &#x003b2;1 integrin inhibitors (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C), among which Praja ring finger ubiquitin ligase 2 (PJA2) and VEGFB. Silencing some (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>A) of these candidate activators (RAP1B, TNS3, and RHOJ) and inhibitors (RACGAP1, PJA2, and VEGFB) identified in our HTS consistently resulted in a clear reduction (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>D) or increase (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>E) in the luminescent signal of &#x003b2;1IAS KI ECs, thus confirming the robustness of the experimental approach. Silencing those proteins in ECs does not affect cell viability (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>B) except VEGFB silencing, being VEGF-B a survival factor.<xref rid="bib64" ref-type="bibr"><sup>60</sup></xref><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>siRNA HTS in &#x003b2;1IAS TeloHAECs to identify activators and inhibitors of &#x003b2;1 integrin</p><p>(A) Schematic of the high-throughput screening (HTS)-selected genes (194), among the 2,970 genes expressed by parental WT TeloHAECs, whose silencing in &#x003b2;1IAS KI ECs induces a decreased luminescent signal (<italic>Z</italic> score&#x000a0;&#x0003c;&#x000a0;&#x02212;2), therefore &#x003b2;1 integrin activators (142, in green), and those whose silencing induces an increased luminescent signal (<italic>Z</italic> score&#x000a0;&#x0003e;&#x000a0;2), therefore &#x003b2;1 integrin inhibitors (52, in red).</p><p>(B) Bubble plot representing top integrin focused enriched pathways (adjusted <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) based on candidate genes obtained from the HTS (2&#x000a0;&#x0003c;&#x000a0;<italic>Z</italic> score&#x000a0;&#x0003c;&#x000a0;&#x02212;2). All enriched pathways are listed in <xref rid="mmc3" ref-type="supplementary-material">Table&#x000a0;S2</xref>. The EnrichR combined score is the log of the <italic>p</italic> value from the Fisher exact test multiplied by the <italic>Z</italic> score of the deviation from the expected rank. Bubble color (adjusted <italic>p</italic> value) was computed using the Benjamini-Hochberg method for correction for multiple hypotheses testing. The gene ratio is the overlap between the input list and the gene sets in each gene set library for ranking a pathway&#x02019;s relevance to the input list.</p><p>(C) Luminescent intensity <italic>Z</italic> score mean of three biological replicates for each endothelial gene whose siRNA was contained in the Qiagen Druggable Genome v.3 siRNA library. The listed genes (&#x003b2;1 integrin inhibitors in red and &#x003b2;1 integrin activators in green) were chosen for secondary validation.</p><p>(D) Luminescence of control &#x003b2;1IAS KI ECs (siCTL) and &#x003b2;1IAS KI ECs silenced for RAP1B, TNS3, and RHOJ and then plated on 500&#x000a0;ng/mL FN. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(E) Luminescence of control &#x003b2;1IAS KI ECs (siCTL) and &#x003b2;1IAS KI ECs silenced for RACGAP1, PJA2, and VEGF-B and then plated on 500&#x000a0;ng/mL FN. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p></caption><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec2.3"><title>The E3 ubiquitin ligase Pja2 promotes kindlin-2 degradation and inhibits &#x003b2;1 integrin activation in ECs</title><p id="p0060">The rise in luminescence caused by the loss of PJA2 in human &#x003b2;1IAS KI ECs was efficiently diminished by transduction with silencing resistant murine Pja2 (mPJA2) (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Pja2 is an E3 ubiquitin ligase originally identified for its ability to promote the degradation of the regulatory subunit of protein kinase A (PKA),<xref rid="bib60" ref-type="bibr"><sup>61</sup></xref> which can behave as a force-dependent binding partner of talin-1 via its regulatory subunit.<xref rid="bib61" ref-type="bibr"><sup>62</sup></xref> Additionally, Pja2 fosters the ubiquitin-dependent proteolysis of monopolar spindle-one-binder protein 1 (Mob1), which inhibits the transcriptional regulator yes-associated protein 1 (Yap1).<xref rid="bib62" ref-type="bibr"><sup>63</sup></xref><sup>,</sup><xref rid="bib63" ref-type="bibr"><sup>64</sup></xref> Since in this context, kindlin-2 acts as an adaptor protein, promoting the interaction between Pja2 and Mob1,<xref rid="bib62" ref-type="bibr"><sup>63</sup></xref> we wondered whether Pja2 may inhibit &#x003b2;1 integrin activation (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>C and 4E) by, at least in part, downregulating kindlin-2 levels. Indeed, western blot analysis revealed that the silencing of PJA2 in WT TeloHAECs increases the amounts of kindlin-2, leaving the levels of both talin-1 and Rap1B unchanged (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). Importantly, Pja2 overexpression significantly augmented the polyubiquitination of kindlin-2 (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C), thus suggesting that Pja2 may negatively regulate &#x003b2;1 integrin activation by fostering the ubiquitin-dependent proteolysis of kindlin-2. Moreover, fluorescence confocal microscopy analysis of adhesion sites containing kindlin-2, vinculin, and conformationally active &#x003b2;1 integrin, recognized by the 9EG7 mAb (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D), showed that the lack of Pja2 increases the adhesion site Feret diameter (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>E) and number (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>F) in WT TeloHAECs. Those data suggest that Pja2 negatively regulates &#x003b2;1 integrin activation and focal adhesion formation by decreasing kindlin-2 protein levels.<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>The E3 ubiquitin ligase PJA2 promotes kindlin-2 degradation and inhibits &#x003b2;1 integrin activation in ECs</p><p>(A) Left: western blot showing the expression of PJA2 in WT TeloHAECs after PJA2 silencing and silenced cells transduced with silencing resistant murine PJA2 (mPJA2). Right: luminescence intensity of &#x003b2;1IAS KI ECs plated on 500&#x000a0;ng/mL FN, silenced for PJA2, and rescued with mPJA2. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(B) Western blot showing the expression of kindlin-2, talin-1, and Rap1B in WT TeloHAECs after PJA2 silencing.</p><p>(C) Left: western blot showing ubiquitinated GFP kindlin-2 pulled down by ubiquitin affinity beads in Phoenix cells overexpressing PJA2 or control construct. The first lane corresponds to the incubation of lysate from cells overexpressing control constructs on non-ubiquitinated beads (see <xref rid="sec9" ref-type="sec">STAR Methods</xref>). Right: western blot showing the expression of PJA2 in cells used in the ubiquitinated assay shown on the left.</p><p>(D) Confocal microscopy showing 9EG7<sup>+</sup> active &#x003b2;1 integrin (green), kindlin-2 (red) and vinculin (blue) in WT TeloHAECs plated on 1.5&#x000a0;&#x003bc;g/mL FN and silenced for PJA2. The image insets highlight focal adhesion sites. Scale bar: 20&#x000a0;&#x003bc;m.</p><p>(E) Relative maximum Feret diameter (mFD) of adhesion sites (FA) in WT TeloHAECs silenced for PJA2 compared to siCTL. Data are the mean&#x000a0;&#x000b1; SD of three independent experiments (10 cells each). Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t test.</p><p>(F) Number of adhesion sites (FA) in siCTL and siPJA2 ECs as in (E). Data are the mean&#x000a0;&#x000b1; SD of three independent experiments (9 cells each). Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t test.</p></caption><graphic xlink:href="gr5"/></fig></p></sec><sec id="sec2.4"><title>VEGF-B is an effective inhibitor of &#x003b2;1 integrin activation in ECs</title><p id="p0065">ECs express high levels of autocrine VEGF-B that signals, at least in part, via VEGFR-1, a tyrosine kinase receptor uniquely endowed with extremely weak enzymatic activity.<xref rid="bib64" ref-type="bibr"><sup>60</sup></xref> Our unbiased HTS identified VEGFB as the strongest inhibitor of &#x003b2;1 integrin activation, among genes silenced in &#x003b2;1IAS KI ECs (<xref rid="fig4" ref-type="fig">Figures&#x000a0;4</xref>C and 4E), in agreement with VEGF-B's reported role as an anti-angiogenic<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> and anti-tumor<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> factor. Consistently, stimulation with exogenous VEGF-B rescued the increased luminescence stimulated by endogenous VEGFB silencing in &#x003b2;1IAS KI ECs (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). In addition, confocal fluorescence microscopy revealed how, compared with WT TeloHAECs, siVEGFB cells display an increased Feret diameter and number of adhesion sites in which kindlin-2, vinculin, and 9EG7<sup>+</sup> active &#x003b2;1 integrins localize (<xref rid="fig6" ref-type="fig">Figures&#x000a0;6</xref>B&#x02013;6D). Impedance analysis also demonstrated that the lack&#x000a0;of endogenous VEGF-B in WT TeloHAECs is accompanied by increased cell adhesion and spreading on FN (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>E) and, conversely, how incubation with increasing amounts of exogenous VEGF-B decreases WT TeloHAEC adhesion to and spreading on FN in a concentration-dependent manner (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>F). As the biochemical and molecular mechanisms that VEGF-B employs to signal through VEGFR-1 and/or other membrane receptors are still incompletely defined,<xref rid="bib64" ref-type="bibr"><sup>60</sup></xref> we analyzed by mass spectrometry the phosphoproteome changes in WT TeloHAECs stimulated with exogenous VEGF-B for 15 and 30&#x000a0;min. We found that exogenous VEGF-B induced changes in the phosphorylation levels of hundreds of sites (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7</xref>A and 7B). Because of the effects of VEGF-B on cell adhesion, we focused on changes in proteins involved in cell adhesion and cytoskeleton organization (based on Gene Ontology annotation). After 15&#x000a0;min stimulation, VEGF-B negatively regulated the phosphorylation of the majority of the sites belonging to proteins involved in those functions (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7</xref>A and 7C). The most downregulated sites included SHANK3, which, by competing with talin for Rap1-GTP binding, impairs Rap1-GTP/talin-driven integrin activation,<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref> and MICAL3, a key component of the ECM adhesion-associated cortical microtubule stabilization complexes (CMSCs)<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> that, via KANK proteins, interact with and activate talin and associated integrins<xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>A). Similar results were obtained after 30&#x000a0;min stimulation with VEGF-B (<xref rid="fig7" ref-type="fig">Figures&#x000a0;7</xref>B and 7D). Consistently, confocal fluorescence microscopy analysis showed that the lack of endogenous VEGF-B results in a sizable increase of KANK3 colocalization with talin-1 and 9EG7<sup>+</sup> active &#x003b2;1 integrins at adhesion sites (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>E) of WT TeloHAECs.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>VEGF-B is an effective inhibitor of &#x003b2;1 integrin activation in ECs</p><p>(A) Left: western blot showing the expression of VEGF-B protein in WT TeloHAECs after VEGFB silencing compared to siCTL. Right: luminescence of TeloHAEC &#x003b2;1IAS plated on 500&#x000a0;ng/mL FN and silenced for VEGFB in the presence or absence of exogenous VEGF-B for 15&#x000a0;min. Data are mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: one-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(B) Confocal microscopy showing 9EG7<sup>+</sup> active &#x003b2;1 integrin (green), kindlin-2 (red), and vinculin (blue) in WT TeloHAECs plated on 1.5&#x000a0;&#x003bc;g/mL FN and silenced for VEGFB. The image insets highlight focal adhesion sites. Scale bar: 20&#x000a0;&#x003bc;m.</p><p>(C) Relative maximum Feret diameter (mFD) of adhesion sites (FA) in WT TeloHAECs silenced for VEGFB compared to siCTL. Data are the mean&#x000a0;&#x000b1; SD of three independent experiments (10 cells each). Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t test.</p><p>(D) Number of adhesion sites (FA) in WT TeloHAECs silenced for VEGFB compared to siCTL. Data are the mean&#x000a0;&#x000b1; SD of three independent experiments (9 cells each). Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t test.</p><p>(E) Relative adhesion measured by the xCELLigence system in WT TeloHAECs plated on 1.5&#x000a0;&#x003bc;g/mL FN and silenced for VEGFB. Data are the mean&#x000a0;&#x000b1; SD of five independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p><p>(F) Relative adhesion measured by the xCELLigence system in WT TeloHAECs plated on 1.5&#x000a0;&#x003bc;g/mL FN and treated or not with 100 and 200&#x000a0;ng/mL exogenous VEGF-B. Data are the mean&#x000a0;&#x000b1; SD of three independent experiments. Statistical analysis: two-way ANOVA and Bonferroni&#x02019;s post hoc analysis.</p></caption><graphic xlink:href="gr6"/></fig><fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>VEGF-B modulates the phosphorylation of CMSC mediators</p><p>(A and B) Volcano plots of the phosphoproteome of parental WT TeloHAECs stimulated with VEGF-B or control for 15 (A)&#x000a0;or 30 (B)&#x000a0;min. <italic>n</italic>&#x000a0;= 4 biological replicates. Colored dots are phosphorylation sites of proteins annotated to the GOBP categories &#x0201c;cell adhesion&#x0201d; or &#x0201c;cytoskeleton organization.&#x0201d; Dashed bars separate significantly regulated sites with <italic>p</italic> &#x02264; 0.05 and difference &#x02265;&#x000a0;&#x000b1;0.2. The position of the phosphorylation site within the protein sequence is in parentheses following the gene name.</p><p>(C and D) Heatmaps of the up- and downregulated sites highlighted in the volcano plots in (A)&#x000a0;and (B), respectively. Colors are based on the intensity values measured for the phosphorylated peptide by MaxQuant; purple represents upregulation upon VEGF-B stimulation, and green represents downregulation upon VEGF-B stimulation. An <sup>&#x02217;</sup> indicates a known regulatory site.</p><p>(E) Left: confocal microscopy showing talin-1 (green) and KANK3 (red) in WT TeloHAECs plated on 1.5&#x000a0;&#x003bc;g/mL FN and silenced for VEGFB. The image insets highlight contact sites between talin-1<sup>+</sup> adhesions and the CMSC mediator KANK3. Scale bar: 20&#x000a0;&#x003bc;m. Right: Pearson correlation between talin-1<sup>+</sup> adhesions and the CMSC mediator KANK3. Data are the mean&#x000a0;&#x000b1; SD of two independent experiments (10 cells each). Statistical analysis: two-tailed heteroscedastic Student&#x02019;s t test.</p></caption><graphic xlink:href="gr7"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0070">Allosteric transitions between inactive and active conformations allow integrins to fulfill their key roles in multiple physiological and pathological contexts.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="bib3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="bib4" ref-type="bibr"><sup>4</sup></xref><sup>,</sup><xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Structural studies<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib72" ref-type="bibr"><sup>72</sup></xref> and the exploitation of mAbs recognizing conformation-specific epitopes<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref><sup>,</sup><xref rid="bib73" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> defined the molecular details of the dynamic functional behavior of integrins. However, extracellular secreted factors<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref><sup>,</sup><xref rid="bib76" ref-type="bibr"><sup>76</sup></xref> and downstream signal transduction pathways<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> that modulate integrin allosteric equilibrium<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> have been only in part characterized. Thus, developing bioorthogonal approaches to monitor integrin conformational activation and inhibition in living cells and organisms may allow a wider and more comprehensive deciphering of the biochemical and cellular mechanisms that regulate integrin function <italic>in&#x000a0;vivo</italic>, with the potential for extension into therapeutics.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref></p><p id="p0075">We report the rational design and implementation of &#x003b2;1IAS, a luminescent sensor that allows effective and noninvasive monitoring of the conformational activation state of &#x003b2;1 integrins in living cells. Such a sensor was conceived to detect the oscillatory outward movement of the &#x003b2;1 integrin hybrid domain, which is ultimately responsible for the functional connection between the headpiece opening and the separation of the &#x003b1; and &#x003b2; subunits of the heterodimer,<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> which, respectively, enable integrins to interact with ECM ligands, e.g., FN, and cytoskeletal adaptors, such as talin and kindlin.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Since the swing out of the &#x003b2; subunit hybrid domain is shared by allosteric dynamics driving the conformational activation and/or the binding to ligands of all the integrins described so far,<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> it is conceivable that the molecular strategy underpinning &#x003b2;1IAS may be harnessed to generate as many integrin activation sensors. In this regard, the extremely low mutual affinity of LgBiT and SmBiT<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> incorporated within the S<sub>79</sub>-K<sub>85</sub> loop, which moves coordinately with the outward swinging hybrid domain,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> together with its reversibility, appears to let &#x003b2;1IAS report the allosteric activation of &#x003b2;1 integrin noninvasively and accurately.</p><p id="p0080">Our analyses on the recombinant extracellular domain of &#x003b1;5&#x003b2;1IAS and &#x003b2;1IAS either transduced in <italic>&#x003b2;1</italic><sup>&#x02212;/&#x02212;</sup> MEFs or genetically expressed in &#x003b2;1IAS KI ECs illustrate how &#x003b2;1IAS acts as a sensor that perceives the modulation of the conformational activation state of &#x003b2;1 integrin by leg separation, ligand binding, metal ions, and ECM ligand specificity, amounts, and stiffness. Moreover, in luminescence microscopy, the &#x003b2;1IAS active conformer glows photons in discrete plasma membrane areas that are similar to <italic>bona fide</italic> ECM adhesion sites. &#x003b2;1IAS also proved a faithful reporter of &#x003b2;1 integrin allosteric modulation upon treating cells either with mAbs known to recognize and stabilize active (9EG7<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> and 12G10<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib33" ref-type="bibr"><sup>33</sup></xref>) or inactive (mAb13)<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> &#x003b2;1 integrins or with the pan-&#x003b1;v integrin and &#x003b1;5&#x003b2;1 integrin antagonist inhibitor MK-0429<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref><sup>,</sup><xref rid="bib36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> or after silencing &#x003b2;1 integrin activators<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref><sup>,</sup><xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> (TLN1, FERMT2, and FERMT3) or inhibitors<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib39" ref-type="bibr"><sup>39</sup></xref><sup>,</sup><xref rid="bib40" ref-type="bibr"><sup>40</sup></xref><sup>,</sup><xref rid="bib75" ref-type="bibr"><sup>75</sup></xref> (FLRT2, LPHN2, and PLXND1). In sum, &#x003b2;1IAS, both as a recombinant protein and in live cells, behaves as an effective luminescent reporter of the &#x003b2;1 integrin conformational activation state in response to multiple biochemical or physical cues.</p><p id="p0085">Our unbiased interrogation in siRNA HTS of about 3,000 genes expressed in &#x003b2;1IAS KI ECs substantiated the validity and robustness of &#x003b2;1IAS but also proved how the sensor may be effectively exploited to identify regulators of the function and activation of &#x003b2;1 and, possibly, other integrins, with the perspective of scaling up the analysis. Indeed, bioinformatics of candidates emerged in the screening as genes coding for &#x003b2;1 integrin positive regulators identified those governing integrin-based focal adhesion formation and signaling, in addition to angiogenesis, as the most represented signaling pathways. Among the activators and positive regulators of &#x003b2;1 integrins, the siRNA HTS on &#x003b2;1IAS KI ECs fittingly identified ECM ligands (TINAGL1<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref>), structural and signaling regulators and adaptors of integrin-based adhesion sites (TNS3,<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> RHOJ,<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> and BCAR1/p130Cas and its interactor CFLAR<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref>), proteins involved in the recycling of endocytosed &#x003b2;1 integrin (RASA1/p120RASGAP<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> and RAB1A<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref>) and its rescue from lysosomal degradation (SNX17<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref>), angiogenic factors and their signaling pathways (FGFR1,<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> ANG,<xref rid="bib55" ref-type="bibr"><sup>55</sup></xref> and SEMA4D and its receptor PLXNB1<xref rid="bib56" ref-type="bibr"><sup>56</sup></xref><sup>,</sup><xref rid="bib57" ref-type="bibr"><sup>57</sup></xref>), and the key small GTPase directly involved in the activation of talin-1 and integrins, namely RAP1B.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="bib42" ref-type="bibr"><sup>42</sup></xref></p><p id="p0090">The less grasped aspect of integrin allosteric regulation is the identification of inhibitory signaling pathways,<xref rid="bib76" ref-type="bibr"><sup>76</sup></xref><sup>,</sup><xref rid="bib77" ref-type="bibr"><sup>77</sup></xref> whose modulation may also be exploited for therapeutic purposes.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> In addition to a few previously described negative regulators, e.g., PLAUR<xref rid="bib58" ref-type="bibr"><sup>58</sup></xref> and RACGAP1,<xref rid="bib59" ref-type="bibr"><sup>59</sup></xref> a number of hitherto undisclosed candidate &#x003b2;1 integrin inhibitors emerged from the siRNA HTS on &#x003b2;1IAS KI ECs. We identified PJA2 RING E3 ligase<xref rid="bib60" ref-type="bibr"><sup>61</sup></xref> as an effective negative regulator of &#x003b2;1 integrin activation and function in ECs. Confirming and extending previous findings by Song and colleagues,<xref rid="bib62" ref-type="bibr"><sup>63</sup></xref> we showed that Pja2 not only interacts with but also reduces the levels of the cytosolic and activating &#x003b2;1 integrin interactor kindlin-2 by promoting its ubiquitination-dependent degradation. We here discover kindlin-2 as a ubiquitinated target for Pja2, proposing its direct negative role on integrin activation modulation, together with its already known ubiquitinated target, the PKA regulatory subunit, which binds talin-1 in a force-dependent manner.<xref rid="bib61" ref-type="bibr"><sup>62</sup></xref> It will be interesting to investigate whether the ubiquitinating activity of Pja2 on kindlin-2 might be promoted by mechanical stimuli.</p><p id="p0095">Our screening pinpointed VEGFB as the most potent &#x003b2;1 integrin inhibitor among the endothelial genes silenced by the employed library. The inhibitory role that VEGF-B exerts on integrin-mediated EC adhesion to the ECM is consistent with what was reported in some studies on tumor angiogenesis<xref rid="bib65" ref-type="bibr"><sup>65</sup></xref><sup>,</sup><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref><sup>,</sup><xref rid="bib67" ref-type="bibr"><sup>67</sup></xref> but not on angiogenesis associated with the repair of damaged tissues, where VEGF-B would instead appear to promote angiogenesis.<xref rid="bib64" ref-type="bibr"><sup>60</sup></xref> It has been proposed that, through VEGFR-1, VEGF-B may inhibit angiogenesis by counteracting FGFR-1 signaling,<xref rid="bib66" ref-type="bibr"><sup>66</sup></xref> which our screening indeed identified as an activator of &#x003b2;1 integrin in ECs, consistent with previous reports.<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref> However, the signaling pathways regulating VEGFR-1 negative and FGFR-1 positive impacts on &#x003b2;1 integrin activation remain unclear. Our phosphoproteomic mass spectrometry identified the key CMSC component MICAL3<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref> among the substrates, whose phosphorylation is modulated by VEGF-B. CMSCs associate with ECM adhesion sites via the KANK3 adaptor, interacting with and activating talin and integrins.<xref rid="bib69" ref-type="bibr"><sup>69</sup></xref><sup>,</sup><xref rid="bib70" ref-type="bibr"><sup>70</sup></xref><sup>,</sup><xref rid="bib71" ref-type="bibr"><sup>71</sup></xref> The observed increased colocalization among KANK3, talin, and active &#x003b2;1 integrin upon endogenous VEGFB silencing hints that the inhibitory function of VEGF-B may be mediated by the modulation of phosphorylation of CMSC components. Our data also suggest that VEGF-B may inhibit &#x003b2;1 integrin activation by regulating the phosphorylation of the talin inhibitor SHANK3.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="bib68" ref-type="bibr"><sup>68</sup></xref></p><p id="p0100">Among the candidate inhibitors of &#x003b2;1 integrin activation identified in our HTS study, we mention PDZ and LIM domain 7 (PDLIM7), protein phosphatase 1 regulatory subunit 12C (PPP1R12C), and myotubularin-related protein 2 (MTMR2) as examples of regulators of integrin conformation, mechanosensing, and traffic, respectively. Indeed, the lack of the cytoskeletal protein PDLIM7 in mice causes a prothrombotic phenotype and platelet dysfunction<xref rid="bib78" ref-type="bibr"><sup>78</sup></xref> potentially due to the Rap1-dependent conformational hyperactivation of platelet &#x003b1;IIb&#x003b2;3 integrin,<xref rid="bib79" ref-type="bibr"><sup>79</sup></xref> as reported in PDLIM1-knockout mice.<xref rid="bib80" ref-type="bibr"><sup>80</sup></xref> PPP1R12C is, instead, a ubiquitous myosin phosphatase target subunit that reduces actomyosin contractility<xref rid="bib81" ref-type="bibr"><sup>81</sup></xref> and the formation and size of ECM adhesions.<xref rid="bib82" ref-type="bibr"><sup>82</sup></xref> Finally, phosphatidylinositol 3 phosphate (PtdIns3P) phosphatase MTMR2, by dephosphorylating PtdIns3P,<xref rid="bib83" ref-type="bibr"><sup>83</sup></xref> may counteract docking on early endosomes of SNX17 and the ensuing retrieval of endocytosed &#x003b2;1 integrin from lysosomal degradation.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="bib46" ref-type="bibr"><sup>46</sup></xref></p><p id="p0105">In conclusion, &#x003b2;1IAS represents a prototype of an effective noninvasive luminescent sensor that may be exploited in live cells to quantify the conformational activation of integrins because of their modulation by biochemical pathways, physical forces, traffic, and degradation, with possible therapeutic implications, as VEGF-B. The use of this sensor in broader screenings may allow a more detailed charting of the mechanisms governing the activation of &#x003b2;1 integrins, and potentially the other integrin &#x003b2; subunits, in different cultured cell types and tissue contexts of genetically modified animals. Even with the intrinsic limitations due to the long exposure time of luminescence microscopy, this type of sensor may enable a noninvasive study of the subcellular localization dynamics of active integrins. Finally, the strategy that underpins the creation of &#x003b2;1IAS could be exploited to&#x000a0;monitor functionally relevant conformational changes of other receptors and transmembrane proteins in general, e.g., cadherins,<xref rid="bib84" ref-type="bibr"><sup>84</sup></xref><sup>,</sup><xref rid="bib85" ref-type="bibr"><sup>85</sup></xref><sup>,</sup><xref rid="bib86" ref-type="bibr"><sup>86</sup></xref><sup>,</sup><xref rid="bib87" ref-type="bibr"><sup>87</sup></xref> plexins,<xref rid="bib88" ref-type="bibr"><sup>88</sup></xref> LDL,<xref rid="bib89" ref-type="bibr"><sup>89</sup></xref><sup>,</sup><xref rid="bib90" ref-type="bibr"><sup>90</sup></xref> and epidermal growth factor (EGF)<xref rid="bib91" ref-type="bibr"><sup>91</sup></xref> receptors.</p><sec id="sec3.1"><title>Limitations of the study</title><p id="p0110">Although we provided evidence for the sensitivity and exploitability of &#x003b2;1IAS by employing a number of diverse <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> biochemistry, cell biology, and microscopy assays, we cannot formally rule out the possibility that the insertion of NanoBiT split luciferase may affect, at least in part, the balance of &#x003b2;1 integrin conformational activation dynamics. Structural studies will be needed to define the details of how the two NanoBiT subunits interact during &#x003b2;1IAS transition between inactive and active conformations and investigate whether the presence of NanoBiT might affect &#x003b2;1IAS conformational activation dynamics when compared to the WT &#x003b2;1 integrin.</p><p id="p0115">In addition, further investigation is needed to comprehensively characterize the mechanisms by which Pja2 and VEGF-B inhibit the conformational activation of &#x003b2;1 integrin in the vascular endothelium both in culture and <italic>in&#x000a0;vivo</italic> models of, e.g., tumor angiogenesis. Moreover, HTS siRNA data showed that in ECs, &#x003b2;1IAS is more sensitive in detecting positive (142) than negative (52) regulators of &#x003b2;1 integrin conformational activation. This could reflect a real imbalance in the number of ratios between activators and inhibitors or be due to intrinsic biochemical features of &#x003b2;1IAS, whose very nature should be further investigated.</p><p id="p0120">Finally, the HTS approach based on the use of a siRNA library, while allowing the identification of previously unknown and promising regulatory candidates of integrin &#x003b2;1 activation, is certainly not complete, being technically limited by both the number of silenced genes compared to those actively transcribed in ECs and the efficacy of gene silencing within the time frame of the protocol.</p></sec></sec><sec id="sec4"><title>Resource availability</title><sec id="sec4.1"><title>Lead contact</title><p id="p0125">Further information should be directed to and will be fulfilled by the lead contact, Guido Serini (<email>guido.serini@ircc.it</email>).</p></sec><sec id="sec4.2"><title>Materials availability</title><p id="p0130">Plasmids and cell lines generated in this study can be shared upon request.</p></sec><sec sec-type="data-availability" id="sec4.3"><title>Data and code availability</title><p id="p0135">
<list list-type="simple" id="ulist0015"><list-item id="u0030"><label>&#x02022;</label><p id="p0140">Raw data, uncropped blots, and RNA-seq BAM files have been deposited at Figshare, and the mass spectrometry data are at the ProteomeXchange Consortium via the PRIDE<xref rid="bib92" ref-type="bibr"><sup>92</sup></xref> partner repository and publicly available as of the date of publication. Accession numbers are listed in the <xref rid="sec9.1" ref-type="sec">key resources table</xref>.</p></list-item><list-item id="u0035"><label>&#x02022;</label><p id="p0145">This paper does not report original code.</p></list-item><list-item id="u0040"><label>&#x02022;</label><p id="p0150">Any additional information required to re-analyze the data reported in this paper is available from the <xref rid="sec4.1" ref-type="sec">lead contact</xref> upon request.</p></list-item></list>
</p></sec></sec><sec id="sec6"><title>Acknowledgments</title><p id="p0160">This research has received funding from <funding-source id="gs1">AIRC</funding-source> under <award-id award-type="grant" rid="gs1">IG 2018</award-id> - <award-id award-type="grant" rid="gs1">ID. 21315</award-id> - P.I. Serini Guido and <award-id award-type="grant" rid="gs1">IG 2023</award-id> - <award-id award-type="grant" rid="gs1">ID. 28763</award-id> - P.I. Serini Guido; <funding-source id="gs3">FPRC-ONLUS</funding-source> grant &#x0201c;MIUR 2010 Vaschetto&#x02014;5 per mille 2010 MIUR&#x0201d; (to G.S.); <funding-source id="gs13">FPRC</funding-source> 5 per mille Ministero della Salute 2022 CARESS (to G.S.); <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003407</institution-id><institution>Ministero dell&#x02019;Istruzione, dell&#x02019;Universit&#x000e0; e della Ricerca</institution></institution-wrap></funding-source> (<award-id award-type="grant" rid="gs3">PRIN 2020EK82R5</award-id> and <award-id award-type="grant" rid="gs3">P2022C948R</award-id>) (to G.S.); <funding-source id="gs12">Universit&#x000e0; di Torino</funding-source>, Bando Ricerca Locale 2019 (<award-id award-type="grant" rid="gs5">CUP D84I19002940005</award-id>) (to G.S.); <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source> (CRUK) <funding-source id="gs11">Scotland Institute</funding-source> A31287 Advanced Technology Facilities grant <award-id award-type="grant" rid="gs7">A17196</award-id> and <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000289</institution-id><institution>CRUK</institution></institution-wrap></funding-source> grant <award-id award-type="grant" rid="gs9">A29800</award-id> to S.Z.; and <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> grant <award-id award-type="grant" rid="gs10">R01HL131836</award-id> (to J.Z.). We thank Alessandro Bosetti and Promega for sharing NanoBiT plasmid constructs. We are grateful to Luca Cevenini and Olympus for providing the LV200 Bioluminescence Imaging System. Lydia Sorokin and Reinhard F&#x000e4;ssler are gratefully acknowledged for providing the purified human Lam 511 from placenta and &#x003b2;1 integrin-null MEFs, respectively.</p></sec><sec id="sec7"><title>Author contributions</title><p id="p0165">G.S. conceived the project; G.S., G.V., and J.Z. contributed equally to develop the project; G.S., G.V., N.G., M.G., H.Z., K.H., F.C., S.Z., and J.Z. designed the experiments; G.S., J.Z., S.Z., and F.C. supervised the research; H.Z., K.H., F.C., S.Z., and J.Z. provided key reagents, methods, and technologies; G.V., N.G., M.G., H.Z., and K.H. performed the experiments; all authors analyzed the data and interpreted the results; G.V., N.G., M.G., H.Z., K.H., F.C., S.Z., J.Z., and G.S. wrote the paper; and all authors read and approved the manuscript.</p></sec><sec sec-type="COI-statement" id="sec8"><title>Declaration of interests</title><p id="p0170">The authors declare no competing interests.</p></sec><sec id="sec9"><title>STAR&#x02605;Methods</title><sec id="sec9.1"><title>Key resources table</title><p id="p0175">
<table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Mouse anti &#x003b1;-tubulin</td><td>Sigma</td><td>Cat#T5168; Clone: B-5-1-2; RRID:AB_477579</td></tr><tr><td>Mouse anti-vinculin</td><td>Sigma</td><td>Cat#V9131; Clone: hVIN-1; RRID:AB_477629</td></tr><tr><td>Mouse anti-TNS3</td><td>Sigma</td><td>Cat#SAB4200416; Clone: TN-17</td></tr><tr><td>Mouse anti-&#x003b2;1 integrin</td><td>Bio Legend</td><td>Cat#303010; Clone: TS2/16; RRID:AB_314326</td></tr><tr><td>Mouse anti-&#x003b2;1 integrin</td><td>Abcam</td><td>Cat#ab30388; Clone: JB1B; RRID:AB_775736</td></tr><tr><td>Rat anti-active &#x003b2;1 integrin</td><td>BD Bioscience</td><td>Cat#553715; Clone: 9EG7; RRID:AB_395001</td></tr><tr><td>Mouse anti-&#x003b2;1 integrin</td><td>Sigma</td><td>Cat# MAB2247; Clone: 12G10</td></tr><tr><td>Mouse anti-inactive &#x003b2;1 integrin</td><td>EMD Millipore</td><td>Cat#MABT821; Clone: mAb13</td></tr><tr><td>Rabbit anti-NanoLuc</td><td>Promega</td><td>Gift from Promega</td></tr><tr><td>Mouse anti-&#x003b1;5 integrin (IP)</td><td>BD Pharmingen</td><td>Cat#555650; RRID:AB_2233951</td></tr><tr><td>Rabbit anti-&#x003b1;5 integrin (WB)</td><td>Cell Signaling</td><td>Cat#4705S</td></tr><tr><td>Mouse anti-&#x003b1;2 integrin (IP/WB)</td><td>Santa Cruz</td><td>Cat#sc-74466; Clone: C-9; RRID:AB_1124939</td></tr><tr><td>Rabbit anti- &#x003b1;v integrin (IP/WB)</td><td>Abcam</td><td>Cat#ab124968; RRID:AB_11129746</td></tr><tr><td>Mouse anti-Talin-1</td><td>Abcam</td><td>Cat#ab157808; Clone: 8D4; RRID:AB_3076684</td></tr><tr><td>Rabbit anti-PJA2</td><td>Abcam</td><td>Cat#ab272665</td></tr><tr><td>Rabbit anti-kindlin-2</td><td>Atlas antibodies</td><td>Cat#HPA040505; RRID:AB_10673300</td></tr><tr><td>Mouse anti-kindlin-3</td><td>Invitrogen</td><td>Cat#PA5-26932</td></tr><tr><td>Rabbit anti-Rap1B</td><td>Invitrogen</td><td>Cat#PA5-29396; RRID:AB_2546872</td></tr><tr><td>Mouse anti-RhoJ</td><td>Invitrogen</td><td>Cat# MA5-26143; RRID:AB_2725234</td></tr><tr><td>Mouse anti-RacGAP1</td><td>Santa Cruz</td><td>Cat#sc-271110; Clone: A-6; RRID:AB_10611939</td></tr><tr><td>Mouse anti-VEGF-B</td><td>Santa Cruz</td><td>Cat#sc-80442; Clone: J-14I; RRID:AB_1131225</td></tr><tr><td>Rabbit anti-GFP antibody</td><td>Invitrogen</td><td>Cat#A-11122; RRID:AB_221569</td></tr><tr><td>Goat HRP-conjugated anti-mouse</td><td>Jackson Research</td><td>Cat#115-035-003; RRID:AB_10015289</td></tr><tr><td>Goat HRP-conjugated anti-rabbit</td><td>Santa Cruz</td><td>Cat#sc-2054; RRID:AB_631748</td></tr><tr><td>Anti-Rat IgG-488</td><td>Thermo Fisher</td><td>Cat#A21470; RRID:AB_10561519</td></tr><tr><td>Anti-Rabbit IgG-555</td><td>Thermo Fisher</td><td>Cat#A21428; RRID:AB_2535849</td></tr><tr><td>Anti-Mouse IgG-647</td><td>Thermo Fisher</td><td>Cat#A21463; RRID:AB_2535869</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, peptides, and recombinant proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>CellTiter-Glo</td><td>Promega</td><td>G7571</td></tr><tr><td>Nano-Glo</td><td>Promega</td><td>N1110</td></tr><tr><td>Fluorescence Mounting Medium</td><td>DAKO</td><td>S3023</td></tr><tr><td>Dithiothreitol (DTT)</td><td>Sigma</td><td>D0632</td></tr><tr><td>Idodacetamide (IAA)</td><td>Sigma</td><td>I6125</td></tr><tr><td>Endopeptidase Lyc</td><td>New England Biolabs</td><td>Neb#P8101</td></tr><tr><td>Acrylamide</td><td>National Diagnostics</td><td>EC-890</td></tr><tr><td>Human Fibronectin</td><td>R&#x00026;D Systems</td><td>1918-FN</td></tr><tr><td>Human placental collagen type I</td><td>Sigma</td><td>C774</td></tr><tr><td>Human placental laminin 511</td><td>Gift by Lydia Sorokin (Institute of Physiological Chemistry and Pathobiochemistry, University of M&#x000fc;nster, M&#x000fc;nster, Germany)</td><td>Previously characterized and validated in Sixt et&#x000a0;al.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></td></tr><tr><td>Human VEGF-B</td><td>R&#x00026;D Systems</td><td>751-VE</td></tr><tr><td>Poly-D-Lysine</td><td>Gibco</td><td>A3890401</td></tr><tr><td>MK-0429</td><td>MedChem Tronica</td><td>HY-15102</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Critical commercial assays</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Strep-Tactin Superflow Plus resin</td><td>Qiagen</td><td>30004</td></tr><tr><td>Ni-NTA resin</td><td>Qiagen</td><td>88221</td></tr><tr><td>TMTpro16plex kit</td><td>Thermo Fisher</td><td>A44520</td></tr><tr><td>TiO2 titansphere beads</td><td>Hichrom Limited</td><td>5020&#x02013;75010</td></tr><tr><td>ReproSil-Pur-C18-AQ beads</td><td>Dr Maisch GmbH</td><td>r15.aq</td></tr><tr><td>Human 3<sup>rd</sup> generation druggable genome siRNA library</td><td>Qiagen</td><td>1027421</td></tr><tr><td>Ubiquitination Affinity beads</td><td>Cytoskeleton</td><td>UBA01B</td></tr><tr><td>BCA protein assay reagent</td><td>Thermo Fisher</td><td>23225</td></tr><tr><td>Lipofectamine 2000</td><td>Invitrogen</td><td>11668027</td></tr><tr><td>Oligofectamine</td><td>Invitrogen</td><td>12252011</td></tr><tr><td>EGM-2 Endothelial Cell Growth Medium-2 BulletKit</td><td>Lonza</td><td>185303</td></tr><tr><td>DynaGreen&#x02122; CaptureSelect&#x02122; Anti-IgG-Fc (Multi-Species) Magnetic Beads</td><td>Thermo Fisher</td><td>Cat#80108G</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Deposited data</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Raw data</td><td>This paper</td><td>Figshare <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.27842265" id="intref0015">https://doi.org/10.6084/m9.figshare.27842265</ext-link></td></tr><tr><td>Uncropped blots</td><td>This paper</td><td>Figshare <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.27842265" id="intref0020">https://doi.org/10.6084/m9.figshare.27842265</ext-link></td></tr><tr><td>RNAseq.bam files</td><td>This paper</td><td>Figshare <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/m9.figshare.27842265" id="intref0025">https://doi.org/10.6084/m9.figshare.27842265</ext-link></td></tr><tr><td>Proteomic data</td><td>This paper</td><td>PRIDE: <ext-link ext-link-type="pride" xlink:href="https://www.ebi.ac.uk/pride/PXD051442" id="intref0030">PXD051442</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental models: Cell lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Wild-type mouse embryonic fibroblasts (MEFs)</td><td>Gift by Reinhard F&#x000e4;ssler (Max Planck Institute of Biochemistry, Martinsried, Germany)</td><td>Previously characterized and validated in B&#x000f6;ttcher et&#x000a0;al.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td>&#x003b2;1 integrin null (&#x003b2;1<sup>&#x02212;/&#x02212;</sup>) mouse embryonic fibroblasts (MEFs)</td><td>Gift by Reinhard F&#x000e4;ssler (Max Planck Institute of Biochemistry, Martinsried, Germany)</td><td>Previously characterized and validated in B&#x000f6;ttcher et&#x000a0;al.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td>hTERT-immortalized human aortic endothelial cells (TeloHAECs)</td><td>ATCC</td><td>CRL-4052</td></tr><tr><td>Phoenix</td><td>ATCC</td><td>CRL-3213</td></tr><tr><td>HEK293</td><td>ATCC</td><td>CRL-1573</td></tr><tr><td>Expi293F</td><td>ATCC</td><td>Previously characterized and validated in Li et&#x000a0;al.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></td></tr><tr><td>&#x003b2;1IAS-KI-TeloHAECs</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>siGENOME siRNA human TLN1 #1: GAAGAUGGUUGGCGGCAUU</td><td>Dharmacon</td><td>J-012949-05</td></tr><tr><td>siGENOME siRNA human TLN1 #2: GUAGAGGACCUGACAACAA</td><td>Dharmacon</td><td>J-012949-06</td></tr><tr><td>siGENOME siRNA human TLN1 #3: UCAAUCAGCUCAUCACUAU</td><td>Dharmacon</td><td>J-012949-07</td></tr><tr><td>siGENOME siRNA human TLN1 #4: GAGAUGAGGAGUCUACUAU</td><td>Dharmacon</td><td>J-012949-08</td></tr><tr><td>siGENOME siRNA human FERMT2 #1: GCCCAGGACUGUAUAGUAA</td><td>Dharmacon</td><td>L-012753-05</td></tr><tr><td>siGENOME siRNA human FERMT2 #2: CUACAUAUUUCUCUCAACA</td><td>Dharmacon</td><td>L-012753-06</td></tr><tr><td>siGENOME siRNA human FERMT2 #3: GAACUGAGUGUCCAUGUGA</td><td>Dharmacon</td><td>L-012753-07</td></tr><tr><td>siGENOME siRNA human FERMT2 #4: AAUGAAAUCUGGCUUCGUU</td><td>Dharmacon</td><td>L-012753-08</td></tr><tr><td>siGENOME siRNA human FERMT3 #1: CCGAAUUGUACACGAGUAU</td><td>Dharmacon</td><td>J-010677-09</td></tr><tr><td>siGENOME siRNA human FERMT3 #2: UGGAGCAGAUCAAUCGCAA</td><td>Dharmacon</td><td>J-010677-10</td></tr><tr><td>siGENOME siRNA human FERMT3 #3: ACUACAGCUUCUUCGAUUU</td><td>Dharmacon</td><td>J-010677-11</td></tr><tr><td>siGENOME siRNA human FERMT3 #4: ACUACAAGAGCCAGGACGA</td><td>Dharmacon</td><td>J-010677-12</td></tr><tr><td>siGENOME siRNA human RAP1B #1: GAACAACUGUGCAUUCUUA</td><td>Dharmacon</td><td>D-010364-01</td></tr><tr><td>siGENOME siRNA human RAP1B #2: CAAUGAUUCUUGUUGGUAA</td><td>Dharmacon</td><td>D-010364-03</td></tr><tr><td>siGENOME siRNA human RAP1B #3: GACCUAGUGCGGCAAAUUA</td><td>Dharmacon</td><td>D-010364-04</td></tr><tr><td>siGENOME siRNA human RAP1B #4: AGUAUAAGCUAGUCGUUCU</td><td>Dharmacon</td><td>D-010364-05</td></tr><tr><td>siGENOME siRNA<break/>human TNS3 #1: GGAAAUGACUGAUGCUCGA</td><td>Dharmacon</td><td>D-009997-21</td></tr><tr><td>siGENOME siRNA<break/>human TNS3 #2: GGUCCGAACACUUGUACAA</td><td>Dharmacon</td><td>D-009997-22</td></tr><tr><td>siGENOME siRNA<break/>human TNS3 #3: GCUCAUUCAUUGUUCGAGA</td><td>Dharmacon</td><td>D-009997-23</td></tr><tr><td>siGENOME siRNA<break/>human TNS3 #4: GGACGGAUAAGACGGAAGA</td><td>Dharmacon</td><td>D-009997-24</td></tr><tr><td>siGENOME siRNA<break/>human RACGAP1 #1: CAAAUUAUCUCUGAAGUGU</td><td>Dharmacon</td><td>D-008650-01</td></tr><tr><td>siGENOME siRNA<break/>human RACGAP1 #2: CCACAGACACCAGAUAUUA</td><td>Dharmacon</td><td>D-008650-02</td></tr><tr><td>siGENOME siRNA<break/>human RACGAP1 #3: GAACAUCAGCUUCUCAAGA</td><td>Dharmacon</td><td>D-008650-03</td></tr><tr><td>siGENOME siRNA<break/>human RACGAP1 #4: GUAAUCAGGUGGAUGUAGA</td><td>Dharmacon</td><td>D-008650-04</td></tr><tr><td>siGENOME siRNA pool human LPHN2</td><td>Dharmacon</td><td>Previously characterized and validated in Camillo et&#x000a0;al.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></td></tr><tr><td>siGENOME siRNA pool human FLRT2</td><td>Dharmacon</td><td>Previously characterized and validated in Camillo et&#x000a0;al.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref></td></tr><tr><td>siRNA human pool PLXND1</td><td>Sigma</td><td>Previously characterized and validated in Rehman et&#x000a0;al.<xref rid="bib93" ref-type="bibr"><sup>93</sup></xref></td></tr><tr><td>DsiRNA human RHOJ #1:<break/>AUGUUUCUACCAAAGCUAUUAGAAC</td><td>IDT</td><td>hs.Ri.RHOJ.13.1</td></tr><tr><td>DsiRNA human RHOJ #2:<break/>AGCACACUGCUACUUGGAAUGUUCA</td><td>IDT</td><td>hs.Ri.RHOJ.13.2</td></tr><tr><td>DsiRNA human RHOJ #3:<break/>ACCUCUCACUUACGAGCAUGGUGTG</td><td>IDT</td><td>hs.Ri.RHOJ.13.3</td></tr><tr><td>DsiRNA human RHOJ #4:<break/>GAGCAUAAAGAUACGUGUUUAAAAA</td><td>IDT</td><td>hs.Ri.RHOJ.13.4</td></tr><tr><td>DsiRNA human PJA2 #1: GCUUUCAUGUUGGAUGGUAACAATA</td><td>IDT</td><td>hs.Ri.PJA2.13.1</td></tr><tr><td>DsiRNA human PJA2 #2: CUUGUGGUUCAGCAUUGAAUCAAAC</td><td>IDT</td><td>hs.Ri.PJA2.13.2</td></tr><tr><td>DsiRNA human PJA2 #3: GUUGAGACAGUGCAUCCAUUUUCTT</td><td>IDT</td><td>hs.Ri.PJA2.13.3</td></tr><tr><td>DsiRNA human PJA2 #4: GUAUUGCAGAAGCACCCUAAACCTT</td><td>IDT</td><td>hs.Ri.PJA2.13.4</td></tr><tr><td>DsiRNA human VEGFB #1: AUGAAUGUCUGCAUCACUAAAUCCA</td><td>IDT</td><td>hs.Ri.VEGFB.13.1</td></tr><tr><td>DsiRNA human VEGFB #2: GGGCAUGAAUGUCUGCAUCACUAAA</td><td>IDT</td><td>hs.Ri.VEGFB.13.2</td></tr><tr><td>DsiRNA human VEGFB #3: CAGUGUGAAUGCAGACCUAAAAAAAA</td><td>IDT</td><td>hs.Ri.VEGFB.13.3</td></tr><tr><td>DsiRNA human VEGFB #4: GAAUGUCUGCAUCACUAAAUCCAGA</td><td>IDT</td><td>hs.Ri.VEGFB.13.4</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Recombinant DNA</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Human WT &#x003b1;<sub>5</sub>&#x003b2;<sub>1</sub> ectodomain with C-terminal ACID-BASE coiled-coil</td><td>Li et&#x000a0;al.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref></td><td>N/A</td></tr><tr><td>pD2529-CAG-acid coiled coil-Integrin &#x003b1;<sub>5</sub></td><td>This paper</td><td>N/A</td></tr><tr><td>Cas9-2A-EGFP</td><td>ATCC</td><td>N/A</td></tr><tr><td>&#x003b2;1IAS donor plasmid</td><td>ATCC</td><td>N/A</td></tr><tr><td>pCMV6-mPJA2</td><td>Origene</td><td>MR220203L3</td></tr><tr><td>pCMV6</td><td>Origene</td><td>PS100001</td></tr><tr><td>pEGFP-kindlin-2</td><td>Gift by Reinhard F&#x000e4;ssler (Max Planck Institute of Biochemistry, Martinsried, Germany)</td><td>N/A</td></tr><tr><td>pEGFP-N1</td><td>Addgene</td><td>Cat#6085-1</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>PRISM (10.1.0) GraphPad</td><td>GraphPad</td><td><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/" id="intref0035">https://www.graphpad.com/scientific-software/prism/</ext-link></td></tr><tr><td>Fiji (ImageJ)</td><td>NIH</td><td><ext-link ext-link-type="uri" xlink:href="https://imagej.net/software/" id="intref0040">https://imagej.net/software/</ext-link><break/>fiji/downloads</td></tr><tr><td>Leica Application Suite</td><td>Leica</td><td><ext-link ext-link-type="uri" xlink:href="https://www.leica-microsystems.com/products/microscope-software/p/leica-application-suite/" id="intref0045">https://www.leica-microsystems.com/products/microscope-software/p/leica-application-suite/</ext-link></td></tr><tr><td>Summit 4.3 software</td><td>This paper</td><td>N/A</td></tr><tr><td>Real-Time Cell Analyzer (RTCA) software</td><td>ACEA Biosciences/Agilent Technologies</td><td><ext-link ext-link-type="uri" xlink:href="https://www.agilent.com/en/product/cell-analysis/real-time-cell-analysis/rtca-software/software-download" id="intref0050">https://www.agilent.com/en/product/cell-analysis/real-time-cell-analysis/rtca-software/software-download</ext-link></td></tr><tr><td>RCSB Protein DataBank</td><td>NIH</td><td><ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/" id="intref0055">https://www.rcsb.org/</ext-link></td></tr><tr><td>Xcalibur software</td><td>Thermo Fisher</td><td>OPTON-30965</td></tr><tr><td>MaxQuant (software<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> version 1.6.14)</td><td>Cox and Mann<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref></td><td>N/A</td></tr><tr><td>Andromeda search engine</td><td>Cox et&#x000a0;al.<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref></td><td>N/A</td></tr><tr><td>Perseus (software version 1.6.15.0. Reverse)</td><td>Tyanova et&#x000a0;al.<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref></td><td>N/A</td></tr><tr><td>EnrichR package</td><td>This paper</td><td>N/A</td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec9.2"><title>Experimental model and study participant details</title><sec id="sec9.2.1"><title>Cell line and culture</title><p id="p0180">Wild-type and &#x003b2;1<sup>&#x02212;/&#x02212;</sup> integrin Mouse Embryonic Fibroblasts (MEFs) were a kind gift from Reinhard F&#x000e4;ssler (Max Planck Institute of&#x000a0;Biochemistry, Martinsried, Germany) and cultured in DMEM completed with glutamine, penicillin/streptomycin solution (Sigma-Aldrich) and 10% Fetal Bovine Serum (Euroclone). Immortalized Telo Human Aortic Endothelial Cells (TeloHAECs) from American Tissue Cell Culture (ATCC) were used (CRL-4052) and grown with EGM-2 Endothelial Cell Growth Medium-2 BulletKit (Lonza). When poor medium is used, this corresponds to EGM-2 without vascular endothelial growth factor-A (VEGF-A) or other growth factors contained in the BulletKit. To measure cell response to different matrix stiffness, MEF or TeloHAEC cells were plated on human fibronectin, 1918-FN (R&#x00026;D Systems)-coated PAA gels (6% [0.5, 10 or 100&#x000a0;kPa] of gel diluted from 30% Protogel in phosphate buffered saline (PBS), 37.5:1 fixed ratio of acrylamide:bis-acrylamide; EC-890, National Diagnostics), previously prepared in glass slide with removable silicon chamber (IBIDI), according to published methods, with modifications.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> Phoenix cells were purchased from ATCC (CRL-3213) and cultured in DMEM completed with glutamine, penicillin/streptomycin solution (Sigma-Aldrich) and 10% Fetal Bovine Serum (Euroclone).</p></sec><sec id="sec9.2.2"><title>Generation of &#x003b2;1IAS KI ECs</title><p id="p0185">The CRISPR-Cas9 technology knock-in was performed in collaboration with American Tissue Cell Culture (ATCC) and it was exploited to insert the LgBiT (ATGGTCTTCACACTCGAAGATTTCGTTGGGGACTGGGAACAGACAGCCGCCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGCTGCAGAATCTCGCCGTGTCCGTAACTCCGATCCAAAGGATTGTCCGGAGCGGTGAAAATGCCCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGCCGACCAAATGGCCCAGATCGAAGAGGTGTTTAAGGTGGTGTACCCTGTGGATGATCATCACTTTAAGGTGATCCTGCCCTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGCTGAACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTAACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCACCCCCGACGGCTCCATGCTGTTCCGAGTAACCATCAACAGT) and the SmBiT (GTGACCGGCTACCGGCTGTTCGAGGAGATTCTG) cDNAs, separated by a 15 amino acid long Gly-Ser linker, into the primary sequence (exon 4) of human &#x003b2;1 integrin (ITGB1) gene, corresponding to the S<sub>79</sub>-K<sub>85</sub> loop of the ternary structure, as shown in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A.</p></sec><sec id="sec9.2.3"><title>gRNA design</title><p id="p0190">Three gRNAs (one binding to the sense strand and the other two to the antisense one) were selected to be less than 15 nucleotides (nt) apart from the target insertion site and predicted to have low off-targets. gRNA #1 sequence: AATGTAACCAACCGTAGCAAAGG, gRNA #2: TGCTGTTCCTTTGCTACGGTTGG and gRNA #3: TCTCTGCTGTTCCTTTGCTACGG. Each gRNA was cloned into Cas9-2A-EGFP vector and Neon transfected together with the donor plasmid into TeloHAEC cells.</p></sec><sec id="sec9.2.4"><title>Donor design</title><p id="p0195">The donor was designed so that the plasmid DNA contains the Gly-Ser linker separated LgBiT and the SmBiT sequences (555&#x000a0;bp) inserted into the target site of exon 4 of human &#x003b2;1 integrin gene, flanked by a 800&#x000a0;bp Left Homology Arm (LHA) and a 800&#x000a0;bp Right Homology Arm (RHD).</p><p id="p0200">The selected gRNA (g1) into the Cas9-2A-EGFP vector was Neon transfected with the donor plasmid into parental wild type TeloHAECs that were then single clone selected by GFP sorting and limiting dilution. After clone expansion, genomic DNA was extracted and sequence was confirmed by Sanger sequencing.</p></sec></sec><sec id="sec9.3"><title>Method details</title><sec id="sec9.3.1"><title>Recombinant proteins and luminescence assay</title><p id="p0205">Human wild type &#x003b1;<sub>5</sub>&#x003b2;<sub>1</sub> ectodomain with C-terminal ACID-BASE coiled-coil, Strep-Tag II, and His-tag was expressed in HEK293 cells as described before.<xref rid="bib74" ref-type="bibr"><sup>74</sup></xref> The protein was purified using Strep-Tactin Superflow Plus resin (Qiagen) and gel filtrated using Superdex 200 Increase 10/300 GL (Cytiva). For the construct of &#x003b1;<sub>5</sub>&#x003b2;<sub>1</sub> IAS ectodomain, integrin &#x003b1;<sub>5</sub> was cloned into pD2529-CAG-acid coiled coil vector with Strep-Tag II, &#x003b2;1IAS was cloned into pD2529-CAG-basic coiled coil vector with His-tag. An HRV 3C protease cleave site was present before the coiled coil sequence in both subunits. The protein was expressed in Expi293F cells and purified using Ni-NTA resin (Qiagen), and then concentrated and buffer exchanged in TBS buffer (25&#x000a0;mM Tris pH 8.0, 150&#x000a0;mM NaCl, 1mM Ca<sup>2+</sup>, 1mM Mg<sup>2+</sup>). Western blot was used to confirm the presence of &#x003b1;5&#x003b2;1IAS. Wild type &#x003b1;5&#x003b2;1 ectodomain was used as control. Purified unclasped &#x003b1;5&#x003b2;1IAS or wild type &#x003b1;5&#x003b2;1 integrin ectodomains were generated by incubating their clasped counterparts overnight at room temperature with HRV 3C protease, in a 1:100 protease to integrin weight ratio.</p><p id="p0210">200&#x000a0;&#x003bc;L of TBS buffer (Ctl), TBS buffer with 5% BSA, or TBS buffer with 5&#x000a0;&#x003bc;g/mL FN was added into each well of 96 well plate and incubated overnight at 4&#x000b0;C. The wells were washed three times with TBS buffer. 50&#x000a0;&#x003bc;L of the purified &#x003b1;5&#x003b2;1IAS ectodomain treated with or without HRV 3C protease in TBS buffer containing either 1&#x000a0;mM Ca<sup>2+/</sup>Mg<sup>+</sup> or additional 2&#x000a0;mM Mn<sup>2+</sup> was added into each well and incubated for 20&#x000a0;min. 50&#x000a0;&#x003bc;L of NanoBiT Luciferase Assay Substrate (Promega) was added into each well and incubated for 5&#x000a0;min. The luminescence intensity was measurement using EnVision 2105 multimode plate reader (PerkinElmer).</p></sec><sec id="sec9.3.2"><title>Luminescence assay in living cells</title><p id="p0215">For experiments on increasing FN, Coll I, Lam 511 amounts and stiffness, solid-white flat 96-well plate was coated with 500&#x000a0;ng/mL FN for 1&#x000a0;h at 37&#x000b0;C and then saturated with 3% BSA in PBS for 1h at 37&#x000b0;C. Next, 8&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> cells/well (MEFs or ECs) were plated in triplicates&#x000a0;and let adhere for 30&#x000a0;min. For experiments with 9EG7 (10&#x000a0;&#x003bc;g/mL), 12G10 (10&#x000a0;&#x003bc;g/mL), mAb13 (10&#x000a0;&#x003bc;g/mL) and MK-0429 (100&#x000a0;&#x003bc;M), cells were given the treatment, while adhering for 15&#x000a0;min in complete medium. For experiments with VEGF-B, cells were added to each well in presence or not with 200&#x000a0;ng/mL of VEGF-B in poor medium for 15&#x000a0;min. Next, NanoBiT Luciferase Assay Substrate (Promega) was added 1:80 in OptiMEM to each well. After 10&#x000a0;min (included in the adhesion time) incubation at 37&#x000b0;C, the luminescent signal was detected with the Spark multimode microplate reader (Spark). For clarity, the 10&#x000a0;min of incubation with the NanoBiT Luciferase Assay Substrate was always included in the final adhesion timing tested.</p></sec><sec id="sec9.3.3"><title>siRNA-based high throughput screening (HTS)</title><p id="p0220">The siRNA HTS was performed in collaboration with Misvik Biology (Turku, Finland) and the human 3rd generation druggable genome siRNA library (Qiagen), containing 6948 targeting siRNAs (pool of 4 individual siRNAs per gene) together with 1148 control siRNAs was used. Different types of control siRNAs were randomly distributed in the library: GFP, Scrambled, and AllStars negative control. For the HTS experiments, 24x384-well plates were coated with 500&#x000a0;ng/mL FN for 1&#x000a0;h at 37&#x000b0;C and then saturated with 3% BSA in PBS for 1h at 37&#x000b0;C. The Qiagen pooled siRNA library readily diluted in Qiagen siRNA buffer was transferred to the FN-coated wells in a final siRNA concentration of 64&#x000a0;nM per well, using a 96-channel liquid handling robot (Eppendorf EpMotion). Raiman lipid transfection reagent was added to the wells according to manufacturer&#x02019;s protocols (Invitrogen) and incubated for 20&#x000a0;min at room temperature. 6&#x000d7; 10<sup>2</sup> &#x003b2;1IAS KI ECs in complete medium was dispensed in each 384-well plate well and allowed to sediment for 20&#x000a0;min at room temperature. Cells were transfected in complete medium for 72h and then incubated with NanoBiT Luciferase Assay Substrate 1:80 in HBSS buffer for 10&#x000a0;min at 37&#x000b0;C using a Multidrop Combi (Thermo Fisher Scientific) liquid dispenser, and the luminescent signal was detected with Labrox multimode multiplate reader (Uniogen).</p></sec><sec id="sec9.3.4"><title>HTS validation</title><p id="p0225">For HTS candidate validation experiments, &#x003b2;1IAS KI ECs were seeded, in quadruplicates, in solid-white flat 384-well plate coated with 500&#x000a0;ng/mL FN at a concentration of 2&#x000a0;&#x000d7;&#x000a0;10<sup>3</sup> cells/well, the day before oligofection. Oligofection of siRNA duplexes was performed according to manufacturer&#x02019;s protocols (Invitrogen). Briefly, cells were transfected twice (at 0 and 24 h) with 200 pmol of siGENOME Non-Targeting siRNA #1 D-001206-13 as control (siCTL) or siGENOME SMART pools (pool of 4 individual siRNAs per gene) (Dharmacon) for human TLN1, FERMT2, FERMT3, FLRT2, LPHN2, PLXND1, RAP1B, TNS3, RACGAP1 or four siRNA pools (IDT) for human RHOJ, PJA2, VEGFB, in a final siRNA concentration of 200&#x000a0;nM. 24, 48 or 72&#x000a0;h after the second oligofection, cells were incubated with NanoBiT Luciferase Assay Substrate (Promega) 1:80 in OptiMEM for 10&#x000a0;min at 37&#x000b0;C, and the luminescent signal was detected with Spark multimode microplate reader (Spark). The effect of each gene silencing on cell viability was assessed using CellTiter-Fluor Cell Viability Assay (Promega).</p></sec><sec id="sec9.3.5"><title>MS proteomic analysis</title><p id="p0230">Parental wild type TeloHAECs were plated on 500&#x000a0;ng/mL of FN and let to adhere in presence or not of 200&#x000a0;ng/mL of human VEGF-B 167 (751-VE, R&#x00026;D System) for 15 or 30&#x000a0;min, in poor medium. Cells were lysed in Chromatin H<sub>2</sub>0, 2.5% sodium dodecyl sulfate (SDS), 250&#x000a0;mM Tris-HCl, pH 6.8, at 95&#x000b0;C. 100&#x000a0;&#x003bc;g of sample from each condition was reduced, alkylated and digested overnight with 5&#x000a0;mM final concentration dithiothreitol (DTT, Sigma), 55&#x000a0;mM idodacetamide (IAA, Sigma), 1:40 Endopeptidase Lyc (New England Biolabs Inc) then 1:100 enzyme to protein trypsin (Promega), respectively. Digested samples were then labeled with 1 x TMTpro16plex kit (Thermo Fisher Scientific) before pooling to a single sample. Phosphorylated peptide enrichment was performed on the pooled sample. TiO2 titansphere (Hichrom Limited) beads were prepared at a 1:5 sample:bead ratio and activated with 80% ACN:6% TFA and slurry placed into a 200&#x000a0;&#x003bc;L tip with a C18 empore disk (3M) stopper. Sample was loaded onto tip and spun slowly through the packed tip at &#x0223c;500 g. This was repeated x 3 before the flow through was collected and loaded onto a fresh tip/slurry mix for a second round of enrichment. Bound phosphorylated peptides were washed with 100&#x000a0;&#x003bc;L 30% ACN:6% TFA then 3 x 100&#x000a0;&#x003bc;L 80% ACN:0.3% TFA before elution with 40&#x000a0;&#x003bc;L 15% NH4OH:40% ACN. Samples were then dried down to complete dryness before fractionation.</p><p id="p0235">Enriched phosphorylated peptides samples were fractionated into 8 fractions using high pH on tip fractionation, utilizing a mix of buffer A, 200&#x000a0;&#x003bc;M ammonium formate pH10, and buffer B, 100% ACN spun through slurry at 1000&#x000a0;g for 1min between each step. Briefly, 50&#x000a0;&#x003bc;L of 3&#x000a0;mg ReproSil-Pur-C18-AQ 5&#x000a0;&#x003bc;m (Dr Maisch GmbH) beads were loaded onto a 200&#x003bc;L tip with a C18 empore disk stopper and allowed to settle for 5&#x000a0;min 50&#x000a0;&#x003bc;L of 100% MeOH was added to activate beads then equilibrated with 200&#x000a0;&#x003bc;M ammonium formate pH10: 50% ACN, then 200&#x003bc;M ammonium formate pH10: 12.5% ACN. 50&#x000a0;&#x003bc;L of 200&#x000a0;&#x003bc;M ammonium formate pH10 was loaded. Sample was re-suspended in 100&#x000a0;&#x003bc;L 200&#x000a0;&#x003bc;M ammonium formate pH10, loaded onto tip and soaked for 10&#x000a0;min before sample loaded. Elution was performed using an increasing % of ACN from fraction 1 to 8: 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20% and 50% respectively.</p><p id="p0240">Peptide samples from each of the 8 fractions were run on an Orbitrap Lumos mass spectrometer (Thermo Scientific) coupled to an EASY-nLC II 1200 chromatography system (Thermo Scientific). Samples were loaded onto a 50&#x000a0;cm fused silica emitter (packed in-house with ReproSIL-Pur Basic C18, 1.9&#x000a0;&#x003bc;m resin, Dr Maisch) which was heated to 50&#x000b0;C using a column oven (Sonation). Samples were run with solvents A (0.1% FA) and B (80% ACN, 0.1% FA). Samples were eluted at a flow rate of 300 nL/min over 8 optimized two-step gradient methods. Step one was commenced for 75&#x000a0;min and step two for 25&#x000a0;min. For fraction 1 the % of solvent B was 2&#x02013;16% at step one and 27% at step two, 3&#x02013;17% then 30%, 3&#x02013;19% then 33%, 4&#x02013;20% then 33%, 4&#x02013;23% then 37%, 7&#x02013;26% then 43%, 8&#x02013;33% then 47%, 9&#x02013;37% then 53% for fractions 2&#x02013;8 respectively. Peptides were electrosprayed into the mass spectrometer using a nanoelectrospray ion source (Thermo Scientific). An Active Background Ion Reduction Device (ESI Solutions) was used to decrease air contaminants.</p><p id="p0245">Data was acquired with Xcalibur software (Thermo Scientific) in positive ion detection mode utilizing data dependent acquisition. Full scan mass (MS1) range was set to 375&#x02013;1400 m/z at 60,000 resolution. Injection time was set to 50&#x000a0;ms with a target value of 3E4 ions. HCD fragmentation was triggered for the top15 most intense ions for MS2 analysis. MS2 injection time was set to 120&#x000a0;ms with a target of 200% AGC, 0.8m/z isolation window and resolution of 50,000. Ions that had already been selected for MS2 were dynamically excluded for 30 s.</p></sec><sec id="sec9.3.6"><title>MS data analysis</title><p id="p0250">Data was processed using MaxQuant software<xref rid="bib94" ref-type="bibr"><sup>94</sup></xref> version 1.6.14 and searched with the Andromeda search engine<xref rid="bib95" ref-type="bibr"><sup>95</sup></xref> against the Uniprot Homo Sapiens database (Swiss-prot, 20,043 entries, 2023). Data was searched with multiplicity set to MS2 level TMT16plex. MS/MS mass tolerance was set to 20 ppm and minimum peptide length was 7 amino acids. Trypsin was selected as the digestion enzyme allowing for 2 missed cleavages and methionine oxidation and N-terminal acetylation and Phospho (STY) was set as variable modifications. Carbamidomethyl was set as a fixed modification. False discovery rate was set to 1%. MaxQuant output was processed using Perseus software<xref rid="bib96" ref-type="bibr"><sup>96</sup></xref> version 1.6.15.0. Reverse and Contaminant Phosphorylation sites were removed and the sites filtered based on a score difference greater than 5 and a localization probability greater than 0.5. Data was normalized by median and logged (log2). For comparative analysis, standard Student&#x02019;s T test was applied and sites with a difference of &#x02265;0.2 and a <italic>p</italic>-value &#x02264;0.05 were considered significant. Gene Ontology Biological Process annotations from UniProt curated database and kinase motifs, kinase-substrate interactions, regulatory sites and known sites were added from PhosphoSite Plus<xref rid="bib97" ref-type="bibr"><sup>97</sup></xref> v6.7.1.1 to <xref rid="mmc4" ref-type="supplementary-material">Table&#x000a0;S3</xref>.</p></sec><sec id="sec9.3.7"><title>Microscopy</title><sec id="sec9.3.7.1"><title>Confocal microscopy</title><p id="p0255">Cells, previously fixed for 10&#x000a0;min in PBS 2% paraformaldehyde (PFA) on wet ice, were permeabilized with Triton 0.1% in PBS for 2&#x000a0;min at 4&#x000b0;C. Primary antibodies were diluted in PBS 1% donkey serum for 1h at room temperature and revealed by appropriate secondary antibodies labeled with fluorochromes (Alexa , Invitrogen), diluted in PBS 1% donkey serum 1:100 for 30&#x000a0;min at room temperature. Only for 9EG7 active integrin staining, the primary antibody was given to live cells (10&#x000a0;&#x003bc;g/mL in complete medium) for 15&#x000a0;min and then PFA fixed, permeabilized and stained as described. The slides were mounted on a microscope slide using Fluorescence Mounting Medium (DAKO) and were allowed to dry overnight at room temperature. The cells were observed under a confocal microscope (TCS SP8 AOBS, Leica Microsystems, Mannheim, Germany). For image acquisition we used a 63&#x000d7; oil-immersion objective (N.A. 1.32). Image acquisition was performed by adopting the same laser power, gain, and offset settings for all the images of the same experiment and avoided saturation.</p><p id="p0260">Images were analyzed using the Leica Application Suite (for colocalization analysis) or ImageJ quantification tool (for relative mFeret Diameter, mFD).</p></sec><sec id="sec9.3.7.2"><title>Luminescence microscopy</title><p id="p0265">Wild-type or transduced cells with &#x003b2;1IAS or NanoLuc alone were plated on fibronectin (3&#x000a0;&#x003bc;g/mL) and let adhere in a glass bottom &#x003bc;-slide 8-well (ibidi) for 3 h. 10&#x000a0;min before imaging, cells well incubated with NanoBiT Luciferase Assay Substrate (Promega) 1:80 in OptiMEM at 37&#x000b0;C. The luminescent signal was observed under a luminescent microscope (Luminoview, LV-200 MD, Olympus, Shinjuku, Japan). For image acquisition we used a 40&#x000d7; oil-immersion objective (N.A. 1.30). Image acquisition was performed by adopting the same laser power, gain, and offset settings for all the images of the same experiment and avoided saturation.</p></sec><sec id="sec9.3.7.3"><title>Flow cytometry analysis</title><p id="p0270">Cells were trypsinized, aliquoted (0.5&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> cells per condition) and washed with 1% BSA in PBS (FACS buffer). Then, the cells were resuspended and incubated with the primary antibody (30&#x02032; on ice) on oversaturating concentration (2&#x003bc;g). Unbound primary antibody was washed away by washing in FACS buffer and the resuspended cells were incubated with 1&#x000a0;&#x003bc;g Alexa Fluor 488-conjugated Donkey anti-rat for 30&#x000a0;min. After a wash in FACS buffer, cells were resuspended in 500&#x003bc;L of PBS.</p><p id="p0275">All samples were acquired using Summit 4.3 software on a Dako CyAN ADP flow cytometer.</p></sec></sec><sec id="sec9.3.8"><title>Western blot analysis</title><p id="p0280">Cells were warm lysed in H<sub>2</sub>0 buffer containing 25% Sodium Dodecyl Sulfate (SDS), 25&#x000a0;mM Tris-HCl, 100&#x000a0;mM NaCl, pH 7.6 at 95&#x000b0;C. The total protein amount was determined using the bicinchoninic acid (BCA) protein assay reagent (Thermo Fisher Scientific). Equivalent amount of protein (20&#x02013;30&#x000a0;&#x003bc;g) was separated by SDS&#x02013; polyacrylamide gel electrophoresis (PAGE) with precast Bolt 4&#x02013;12% Bis-Tris gel (Thermo Fisher Scientific). Proteins were then transferred to a nitrocellulose membrane (Bio-Rad), blocked in 5% Bovine serum albumin (BSA) buffer for 1h at RT, incubated with appropriate primary antibodies in PBS-Tween 0.1%, overnight at 4&#x000b0;C or 1h at RT. The HRP-conjugated secondary antibodies were detected by enhanced chemiluminescence technique (BioRad).</p></sec><sec id="sec9.3.9"><title>Immunoprecipitation</title><p id="p0285">To immunoprecipitate and analyze by Western blot &#x003b2;1IAS dimerization with other &#x003b1; integrin subunits, &#x003b2;1IAS ECs were washed 3 times with PBS and lysed with a buffer containing 25&#x000a0;mM Tris&#x02013;HCl pH 7.6, 100&#x000a0;mM NaCl, 0.15% Tween 20, 5% glycerol, 0.5&#x000a0;mM EGTA, 2&#x000a0;mM MgCl<sub>2</sub>, 1&#x000a0;mM PMSF, 1&#x000a0;mM Na<sub>3</sub>VO<sub>4</sub>, and protease inhibitor cocktail (Sigma Aldrich). Cellular lysates were incubated for 20&#x000a0;min on ice and then centrifuged at 15,000 <italic>g</italic>, 20&#x000a0;min, at 4&#x000b0;C. The total protein amount was determined using the bicinchoninic acid (BCA) protein assay reagent (Thermo Fisher Scientific). Equivalent amount (1&#x000a0;mg) of protein were precipitated for 1&#x000a0;h at 4&#x000b0;C with DynaGreen CaptureSelect Anti-IgG-Fc (Multi-Species) Magnetic Beads (Thermo Fisher Scientific) and then centrifuged for 1&#x000a0;min 15,000 <italic>g</italic> at 4&#x000b0;C. DynaGreen Magnetic beads were collected and incubated with the anti-&#x003b1;5, &#x003b1;2 or &#x003b1;v antibodies for 1&#x000a0;h at 4&#x000b0;C. Immunoprecipitates were washed four times with lysis buffer and then separated by SDS&#x02013;PAGE. Proteins were then transferred to a nitrocellulose membrane (Bio-Rad), probed with NanoBiT antibody, and detected by enhanced chemiluminescence technique (PerkinElmer).</p></sec><sec id="sec9.3.10"><title>Ubiquitin assay</title><p id="p0290">Pja2 and kindlin-2 levels were co-overexpressed in Phoenix cells by Lipofectamine 2000 transfection reagent (Invitrogen) in OptiMEM, for 5&#x000a0;h at 37&#x000b0;C. Cells were also co-transfected with kindlin-2 together with a control vector. After overnight growth in standard conditions, cells were lysed as described above. 1.5&#x000a0;mg of each lysate was incubated on 20&#x000a0;&#x003bc;L of reconstituted UBA01B-beads (Cytoskeleton) for 2&#x000a0;h at 4&#x000b0;C. Moreover, as described by the bead manufacturer, 20&#x000a0;&#x003bc;L of reconstituted control beads (Cytoskeleton) were incubated with lysate of Phoenix cells co-transfected with both control vectors in the same conditions. Protein run was performed as previously described and ubiquitinated kindlin-2 levels were detected with GFP antibody (Invitrogen, A-11122).</p></sec><sec id="sec9.3.11"><title>Cell spreading assay</title><p id="p0295">Real-time adhesion of MEFs or ECs was monitored with an xCELLigence, an electrical impedance-based system in which microelectronic sensor arrays are integrated into the bottom of microplate wells, allowing cells in the wells to be constantly monitored. The xCELLigence system is based on the Real-Time Cell Analyzer (RTCA) instrument (ACEA Biosciences/Agilent Technologies). Its software converts impedance values to obtain parameters such as cell index (CI), mean values, and standard deviation (SD). In detail, the bottom side of the E-Plate 16 was coated with 1.5&#x000a0;&#x003bc;g/mL FN for 1&#x000a0;h at room temperature. Then, the protein-coated plate was washed with PBS and incubated with 3% BSA solution in PBS for 1&#x000a0;h at 37&#x000b0;C. Cells were detached by means of trypsin-EDTA and resuspended to a final concentration of 8000 cells/100&#x000a0;&#x003bc;L. The BLANK step was started to measure the background impedance of cell culture medium, which was then used as reference impedance for calculating CI values. 100&#x000a0;&#x003bc;L of cell suspension (8000 cells) was then added to each well. For spreading assay with VEGF-B, cells were added to each well in presence or not with 100 or 200&#x000a0;ng/mL of VEGF-B in poor medium. The E-Plate 16 was placed in the RTCA DP Instrument equilibrated in a CO2 incubator. Cells adhesion was continuously monitored using the RTCA DP instrument. Mean, SD, and <italic>p</italic>-value were calculated on the CI data, exported from the RTCA instrument, including the technical replicates of each experimental condition at each time-point.</p></sec><sec id="sec9.3.12"><title>RNA sequencing</title><p id="p0300">RNA sequencing was performed on &#x003b2;1IAS KI ECs in three independent experiments by Misvik Biology. The RNA libraries were sequenced on a paired-end read flow cell by bridge amplification and 150 cycles sequencing-by- synthesis on the Illumina NovaSeq 6000 S4 platform (Illumina Inc., San Diego, CA, USA). The average number of raw reads obtained was 39.3 million.</p></sec><sec id="sec9.3.13"><title>Bioinformatics analysis</title><p id="p0305">The RNA-sequencing (RNA-seq) reads were aligned to the reference genome v hg38/GRC38 using Bowtie v 2.3.3.1, the annotation was performed on Gencode v29. Read count and normalization analysis was performed with DESeq2 v1.38.3. A transcript is considered in the analysis if associated with a median value of reads &#x0003e;20.</p><p id="p0310">Enrichment analysis was performed on 194 candidate genes selected setting using a <italic>Z</italic> score threshold equals to 2 standard deviations. EnrichR web-based tool was used to combine KEGG, WikiPathways, NCI-Nature, BioPlanet databases. Only terms associated with an adjusted <italic>p</italic>-value &#x0003c;0.05 were considered as significant. Among the significant pathways, those related to integrin function and to cell adhesion were chosen for representation.</p></sec></sec><sec id="sec9.4"><title>Quantification and statistical analysis</title><p id="p0315">For statistical evaluation, data distribution was assumed to be normal. Parametric two-tailed heteroscedastic Student&#x02019;s t-test was used to assess the statistical significance when two groups of unpaired normally distributed values were compared; when more than two groups were compared, parametric two-tailed analysis of variance (ANOVA) with Bonferroni&#x02019;s correction was applied. Selected <italic>p</italic> values are shown as absolute values and all <italic>p</italic> values are included in <xref rid="mmc2" ref-type="supplementary-material">Table&#x000a0;S1</xref>.</p><p id="p0320">For each experiment, we performed 2&#x02013;5 independent biological replicates, in which at least three or four technical replicates were performed. Then, to analyze the reproducibility, we calculated the mean of the independent biological replicates&#x000a0;&#x000b1;SD and performed statistical analyses.</p><p id="p0325">For HTS data analysis, normalization of the detected luminescent raw signals was performed plate by plate based on GFP, Scrambled and AllStars negative controls. <italic>Z</italic> score was calculated as <inline-formula><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">&#x003c7;</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">&#x003bc;</mml:mi></mml:mrow><mml:mi mathvariant="normal">&#x003c3;</mml:mi></mml:mfrac></mml:mrow></mml:math></inline-formula> of the luminescent emission signal data (<inline-formula><mml:math id="M2" altimg="si2.gif"><mml:mrow><mml:mi mathvariant="normal">&#x003c7;</mml:mi></mml:mrow></mml:math></inline-formula>&#x000a0;= data point, &#x003bc;&#x000a0;= mean, &#x003c3;&#x000a0;= standard deviation).</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Seb&#x000e9;-Pedr&#x000f3;s</surname><given-names>A.</given-names></name><name><surname>Degnan</surname><given-names>B.M.</given-names></name><name><surname>Ruiz-Trillo</surname><given-names>I.</given-names></name></person-group><article-title>The origin of Metazoa: a unicellular perspective</article-title><source>Nat. Rev. Genet.</source><volume>18</volume><year>2017</year><fpage>498</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1038/nrg.2017.21</pub-id><pub-id pub-id-type="pmid">28479598</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Moreno-Layseca</surname><given-names>P.</given-names></name><name><surname>Icha</surname><given-names>J.</given-names></name><name><surname>Hamidi</surname><given-names>H.</given-names></name><name><surname>Ivaska</surname><given-names>J.</given-names></name></person-group><article-title>Integrin trafficking in cells and tissues</article-title><source>Nat. Cell Biol.</source><volume>21</volume><year>2019</year><fpage>122</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0223-z</pub-id><pub-id pub-id-type="pmid">30602723</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Aman</surname><given-names>J.</given-names></name><name><surname>Margadant</surname><given-names>C.</given-names></name></person-group><article-title>Integrin-Dependent Cell&#x02013;Matrix Adhesion in Endothelial Health and Disease</article-title><source>Circ. Res.</source><volume>132</volume><year>2023</year><fpage>355</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.122.322332</pub-id><pub-id pub-id-type="pmid">36730379</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Lilja</surname><given-names>J.</given-names></name><name><surname>Ivaska</surname><given-names>J.</given-names></name></person-group><article-title>Integrin activity in neuronal connectivity</article-title><source>J.&#x000a0;Cell Sci.</source><volume>131</volume><year>2018</year><object-id pub-id-type="publisher-id">jcs212803</object-id><pub-id pub-id-type="doi">10.1242/jcs.212803</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>van der Meijden</surname><given-names>P.E.J.</given-names></name><name><surname>Heemskerk</surname><given-names>J.W.M.</given-names></name></person-group><article-title>Platelet biology and functions: new concepts and clinical perspectives</article-title><source>Nat. Rev. Cardiol.</source><volume>16</volume><year>2019</year><fpage>166</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0110-0</pub-id><pub-id pub-id-type="pmid">30429532</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>M.A.</given-names></name><name><surname>Margadant</surname><given-names>C.</given-names></name></person-group><article-title>Activation and suppression of hematopoietic integrins in hemostasis and immunity</article-title><source>Blood</source><volume>135</volume><year>2020</year><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003336</pub-id><pub-id pub-id-type="pmid">31730155</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>E.S.</given-names></name><name><surname>Weyrich</surname><given-names>A.S.</given-names></name><name><surname>Zimmerman</surname><given-names>G.A.</given-names></name></person-group><article-title>Lessons from rare maladies: leukocyte adhesion deficiency syndromes</article-title><source>Curr. Opin. Hematol.</source><volume>20</volume><year>2013</year><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">23207660</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Hamidi</surname><given-names>H.</given-names></name><name><surname>Ivaska</surname><given-names>J.</given-names></name></person-group><article-title>Every step of the way: integrins in cancer progression and metastasis</article-title><source>Nat. Rev. Cancer</source><volume>18</volume><year>2018</year><fpage>533</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0038-z</pub-id><pub-id pub-id-type="pmid">30002479</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Costell</surname><given-names>M.</given-names></name><name><surname>F&#x000e4;ssler</surname><given-names>R.</given-names></name></person-group><article-title>Integrin activation by talin, kindlin and mechanical forces</article-title><source>Nat. Cell Biol.</source><volume>21</volume><year>2019</year><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0234-9</pub-id><pub-id pub-id-type="pmid">30602766</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Kanchanawong</surname><given-names>P.</given-names></name><name><surname>Calderwood</surname><given-names>D.A.</given-names></name></person-group><article-title>Organization, dynamics and mechanoregulation of integrin-mediated cell&#x02013;ECM adhesions</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>24</volume><year>2023</year><fpage>142</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00531-5</pub-id><pub-id pub-id-type="pmid">36168065</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Slack</surname><given-names>R.J.</given-names></name><name><surname>Macdonald</surname><given-names>S.J.F.</given-names></name><name><surname>Roper</surname><given-names>J.A.</given-names></name><name><surname>Jenkins</surname><given-names>R.G.</given-names></name><name><surname>Hatley</surname><given-names>R.J.D.</given-names></name></person-group><article-title>Emerging therapeutic opportunities for integrin inhibitors</article-title><source>Nat. Rev. Drug Discov.</source><volume>21</volume><year>2022</year><fpage>60</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1038/s41573-021-00284-4</pub-id><pub-id pub-id-type="pmid">34535788</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>I.D.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>Integrin structure, activation, and interactions</article-title><source>Cold Spring Harbor Perspect. Biol.</source><volume>3</volume><year>2011</year><object-id pub-id-type="publisher-id">a004994</object-id><pub-id pub-id-type="doi">10.1101/cshperspect.a004994</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Bachmann</surname><given-names>M.</given-names></name><name><surname>Kukkurainen</surname><given-names>S.</given-names></name><name><surname>Hyt&#x000f6;nen</surname><given-names>V.P.</given-names></name><name><surname>Wehrle-Haller</surname><given-names>B.</given-names></name></person-group><article-title>Cell Adhesion by Integrins</article-title><source>Physiol. Rev.</source><volume>99</volume><year>2019</year><fpage>1655</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">31313981</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Carlson</surname><given-names>T.R.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Braren</surname><given-names>R.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name><name><surname>Wang</surname><given-names>R.A.</given-names></name></person-group><article-title>Cell-autonomous requirement for &#x003b2;1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice</article-title><source>Development</source><volume>135</volume><year>2008</year><fpage>2193</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.1242/dev.016378</pub-id><pub-id pub-id-type="pmid">18480158</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Henning</surname><given-names>C.</given-names></name><name><surname>Branopolski</surname><given-names>A.</given-names></name><name><surname>Follert</surname><given-names>P.</given-names></name><name><surname>Lewandowska</surname><given-names>O.</given-names></name><name><surname>Ayhan</surname><given-names>A.</given-names></name><name><surname>Benkhoff</surname><given-names>M.</given-names></name><name><surname>Fl&#x000f6;gel</surname><given-names>U.</given-names></name><name><surname>Kelm</surname><given-names>M.</given-names></name><name><surname>Heiss</surname><given-names>C.</given-names></name><name><surname>Lammert</surname><given-names>E.</given-names></name></person-group><article-title>Endothelial &#x003b2;1 Integrin-Mediated Adaptation to Myocardial Ischemia</article-title><source>Thromb. Haemost.</source><volume>121</volume><year>2021</year><fpage>741</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1721505</pub-id><pub-id pub-id-type="pmid">33469904</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H.</given-names></name><name><surname>Ehling</surname><given-names>M.</given-names></name><name><surname>Kato</surname><given-names>K.</given-names></name><name><surname>Kanai</surname><given-names>K.</given-names></name><name><surname>van Lessen</surname><given-names>M.</given-names></name><name><surname>Frye</surname><given-names>M.</given-names></name><name><surname>Zeuschner</surname><given-names>D.</given-names></name><name><surname>Nakayama</surname><given-names>M.</given-names></name><name><surname>Vestweber</surname><given-names>D.</given-names></name><name><surname>Adams</surname><given-names>R.H.</given-names></name></person-group><article-title>Integrin &#x003b2;1 controls VE-cadherin localization and blood vessel stability</article-title><source>Nat. Commun.</source><volume>6</volume><year>2015</year><fpage>6429</fpage><pub-id pub-id-type="doi">10.1038/ncomms7429</pub-id><pub-id pub-id-type="pmid">25752958</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Nih</surname><given-names>L.R.</given-names></name><name><surname>Bachman</surname><given-names>H.</given-names></name><name><surname>Fei</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Nam</surname><given-names>E.</given-names></name><name><surname>Dimatteo</surname><given-names>R.</given-names></name><name><surname>Carmichael</surname><given-names>S.T.</given-names></name><name><surname>Barker</surname><given-names>T.H.</given-names></name><name><surname>Segura</surname><given-names>T.</given-names></name></person-group><article-title>Hydrogels with precisely controlled integrin activation dictate vascular patterning and permeability</article-title><source>Nat. Mater.</source><volume>16</volume><year>2017</year><fpage>953</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/nmat4954</pub-id><pub-id pub-id-type="pmid">28783156</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Serini</surname><given-names>G.</given-names></name><name><surname>Bussolino</surname><given-names>F.</given-names></name><name><surname>Maione</surname><given-names>F.</given-names></name><name><surname>Giraudo</surname><given-names>E.</given-names></name></person-group><article-title>Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy</article-title><source>J.&#x000a0;Intern. Med.</source><volume>273</volume><year>2013</year><fpage>138</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1111/joim.12017</pub-id><pub-id pub-id-type="pmid">23198760</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Gioelli</surname><given-names>N.</given-names></name><name><surname>Maione</surname><given-names>F.</given-names></name><name><surname>Camillo</surname><given-names>C.</given-names></name><name><surname>Ghitti</surname><given-names>M.</given-names></name><name><surname>Valdembri</surname><given-names>D.</given-names></name><name><surname>Morello</surname><given-names>N.</given-names></name><name><surname>Darche</surname><given-names>M.</given-names></name><name><surname>Zentilin</surname><given-names>L.</given-names></name><name><surname>Cagnoni</surname><given-names>G.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent</article-title><source>Sci. Transl. Med.</source><volume>10</volume><year>2018</year><object-id pub-id-type="publisher-id">eaah4807</object-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aah4807</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>J.D.</given-names></name><name><surname>Seano</surname><given-names>G.</given-names></name><name><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges</article-title><source>Annu. Rev. Physiol.</source><volume>81</volume><year>2019</year><fpage>505</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114700</pub-id><pub-id pub-id-type="pmid">30742782</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Nagae</surname><given-names>M.</given-names></name><name><surname>Re</surname><given-names>S.</given-names></name><name><surname>Mihara</surname><given-names>E.</given-names></name><name><surname>Nogi</surname><given-names>T.</given-names></name><name><surname>Sugita</surname><given-names>Y.</given-names></name><name><surname>Takagi</surname><given-names>J.</given-names></name></person-group><article-title>Crystal structure of &#x003b1;5&#x003b2;1 integrin ectodomain: atomic details of the fibronectin receptor</article-title><source>J.&#x000a0;Cell Biol.</source><volume>197</volume><year>2012</year><fpage>131</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1083/jcb.201111077</pub-id><pub-id pub-id-type="pmid">22451694</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Bunch</surname><given-names>T.A.</given-names></name><name><surname>Helsten</surname><given-names>T.L.</given-names></name><name><surname>Kendall</surname><given-names>T.L.</given-names></name><name><surname>Shirahatti</surname><given-names>N.</given-names></name><name><surname>Mahadevan</surname><given-names>D.</given-names></name><name><surname>Shattil</surname><given-names>S.J.</given-names></name><name><surname>Brower</surname><given-names>D.L.</given-names></name></person-group><article-title>Amino Acid Changes in Drosophila &#x003b1;PS2&#x003b2;PS Integrins That Affect Ligand Affinity</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>5050</fpage><lpage>5057</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508550200</pub-id><pub-id pub-id-type="pmid">16371365</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Kendall</surname><given-names>T.</given-names></name><name><surname>Mukai</surname><given-names>L.</given-names></name><name><surname>Jannuzi</surname><given-names>A.L.</given-names></name><name><surname>Bunch</surname><given-names>T.A.</given-names></name></person-group><article-title>Identification of Integrin &#x003b2; Subunit Mutations That Alter Affinity for Extracellular Matrix Ligand</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>30981</fpage><lpage>30993</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.254797</pub-id><pub-id pub-id-type="pmid">21757698</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Huet-Calderwood</surname><given-names>C.</given-names></name><name><surname>Rivera-Molina</surname><given-names>F.</given-names></name><name><surname>Iwamoto</surname><given-names>D.V.</given-names></name><name><surname>Kromann</surname><given-names>E.B.</given-names></name><name><surname>Toomre</surname><given-names>D.</given-names></name><name><surname>Calderwood</surname><given-names>D.A.</given-names></name></person-group><article-title>Novel ecto-tagged integrins reveal their trafficking in live cells</article-title><source>Nat. Commun.</source><volume>8</volume><year>2017</year><fpage>570</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00646-w</pub-id><pub-id pub-id-type="pmid">28924207</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Soto-Ribeiro</surname><given-names>M.</given-names></name><name><surname>Kastberger</surname><given-names>B.</given-names></name><name><surname>Bachmann</surname><given-names>M.</given-names></name><name><surname>Azizi</surname><given-names>L.</given-names></name><name><surname>Fouad</surname><given-names>K.</given-names></name><name><surname>Jacquier</surname><given-names>M.-C.</given-names></name><name><surname>Boettiger</surname><given-names>D.</given-names></name><name><surname>Bouvard</surname><given-names>D.</given-names></name><name><surname>Bastmeyer</surname><given-names>M.</given-names></name><name><surname>Hyt&#x000f6;nen</surname><given-names>V.P.</given-names></name><name><surname>Wehrle-Haller</surname><given-names>B.</given-names></name></person-group><article-title>&#x003b2;1D integrin splice variant stabilizes integrin dynamics and reduces integrin signaling by limiting paxillin recruitment</article-title><source>J.&#x000a0;Cell Sci.</source><volume>132</volume><year>2019</year><object-id pub-id-type="publisher-id">jcs224493</object-id><pub-id pub-id-type="doi">10.1242/jcs.224493</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>England</surname><given-names>C.G.</given-names></name><name><surname>Ehlerding</surname><given-names>E.B.</given-names></name><name><surname>Cai</surname><given-names>W.</given-names></name></person-group><article-title>NanoLuc: A Small&#x000a0;Luciferase Is Brightening Up the Field of Bioluminescence</article-title><source>Bioconjug. Chem.</source><volume>27</volume><year>2016</year><fpage>1175</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00112</pub-id><pub-id pub-id-type="pmid">27045664</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>J.</given-names></name><name><surname>Erickson</surname><given-names>H.P.</given-names></name><name><surname>Springer</surname><given-names>T.A.</given-names></name></person-group><article-title>C-terminal opening mimics &#x0201c;inside-out&#x0201d; activation of integrin &#x003b1;5&#x003b2;1</article-title><source>Nat. Struct. Biol.</source><volume>8</volume><year>2001</year><fpage>412</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/87569</pub-id><pub-id pub-id-type="pmid">11323715</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>J.</given-names></name><name><surname>Petre</surname><given-names>B.M.</given-names></name><name><surname>Walz</surname><given-names>T.</given-names></name><name><surname>Springer</surname><given-names>T.A.</given-names></name></person-group><article-title>Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling</article-title><source>Cell</source><volume>110</volume><year>2002</year><fpage>599</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">12230977</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>B&#x000f6;ttcher</surname><given-names>R.T.</given-names></name><name><surname>Stremmel</surname><given-names>C.</given-names></name><name><surname>Meves</surname><given-names>A.</given-names></name><name><surname>Meyer</surname><given-names>H.</given-names></name><name><surname>Widmaier</surname><given-names>M.</given-names></name><name><surname>Tseng</surname><given-names>H.Y.</given-names></name><name><surname>F&#x000e4;ssler</surname><given-names>R.</given-names></name></person-group><article-title>Sorting nexin 17 prevents lysosomal degradation of &#x003b2;1 integrins by binding to the &#x003b2;1-integrin tail</article-title><source>Nat. Cell Biol.</source><volume>14</volume><year>2012</year><fpage>584</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1038/ncb2501</pub-id><pub-id pub-id-type="pmid">22561348</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Sixt</surname><given-names>M.</given-names></name><name><surname>Engelhardt</surname><given-names>B.</given-names></name><name><surname>Pausch</surname><given-names>F.</given-names></name><name><surname>Hallmann</surname><given-names>R.</given-names></name><name><surname>Wendler</surname><given-names>O.</given-names></name><name><surname>Sorokin</surname><given-names>L.M.</given-names></name></person-group><article-title>Endothelial Cell Laminin Isoforms, Laminins 8 and 10, Play Decisive Roles in T Cell Recruitment across the Blood&#x02013;Brain Barrier in Experimental Autoimmune Encephalomyelitis</article-title><source>J.&#x000a0;Cell Biol.</source><volume>153</volume><year>2001</year><fpage>933</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1083/jcb.153.5.933</pub-id><pub-id pub-id-type="pmid">11381080</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Askari</surname><given-names>J.A.</given-names></name><name><surname>Tynan</surname><given-names>C.J.</given-names></name><name><surname>Webb</surname><given-names>S.E.D.</given-names></name><name><surname>Martin-Fernandez</surname><given-names>M.L.</given-names></name><name><surname>Ballestrem</surname><given-names>C.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>Focal adhesions are sites of integrin extension</article-title><source>J.&#x000a0;Cell Biol.</source><volume>188</volume><year>2010</year><fpage>891</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1083/jcb.200907174</pub-id><pub-id pub-id-type="pmid">20231384</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Byron</surname><given-names>A.</given-names></name><name><surname>Humphries</surname><given-names>J.D.</given-names></name><name><surname>Askari</surname><given-names>J.A.</given-names></name><name><surname>Craig</surname><given-names>S.E.</given-names></name><name><surname>Mould</surname><given-names>A.P.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>Anti-integrin monoclonal antibodies</article-title><source>J.&#x000a0;Cell Sci.</source><volume>122</volume><year>2009</year><fpage>4009</fpage><lpage>4011</lpage><pub-id pub-id-type="doi">10.1242/jcs.056770</pub-id><pub-id pub-id-type="pmid">19910492</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>A.P.</given-names></name><name><surname>Askari</surname><given-names>J.A.</given-names></name><name><surname>Barton</surname><given-names>S.</given-names></name><name><surname>Kline</surname><given-names>A.D.</given-names></name><name><surname>McEwan</surname><given-names>P.A.</given-names></name><name><surname>Craig</surname><given-names>S.E.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>277</volume><year>2002</year><fpage>19800</fpage><lpage>19805</lpage><pub-id pub-id-type="doi">10.1074/jbc.M201571200</pub-id><pub-id pub-id-type="pmid">11893752</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Mould</surname><given-names>A.P.</given-names></name><name><surname>Akiyama</surname><given-names>S.K.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>The inhibitory anti-beta1 integrin monoclonal antibody 13 recognizes an epitope that is attenuated by ligand occupancy. Evidence for allosteric inhibition of integrin function</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>271</volume><year>1996</year><fpage>20365</fpage><lpage>20374</lpage><pub-id pub-id-type="pmid">8702772</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Delouvri&#x000e9;</surname><given-names>B.</given-names></name><name><surname>Al-Kadhimi</surname><given-names>K.</given-names></name><name><surname>Arnould</surname><given-names>J.-C.</given-names></name><name><surname>Barry</surname><given-names>S.T.</given-names></name><name><surname>Cross</surname><given-names>D.A.E.</given-names></name><name><surname>Didelot</surname><given-names>M.</given-names></name><name><surname>Gavine</surname><given-names>P.R.</given-names></name><name><surname>Germain</surname><given-names>H.</given-names></name><name><surname>Harris</surname><given-names>C.S.</given-names></name><name><surname>Hughes</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Structure&#x02013;activity relationship of a series of non peptidic RGD integrin antagonists targeting &#x003b1;5&#x003b2;1: Part 1</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>22</volume><year>2012</year><fpage>4111</fpage><lpage>4116</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.063</pub-id><pub-id pub-id-type="pmid">22575869</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Delouvri&#x000e9;</surname><given-names>B.</given-names></name><name><surname>Al-Kadhimi</surname><given-names>K.</given-names></name><name><surname>Arnould</surname><given-names>J.-C.</given-names></name><name><surname>Barry</surname><given-names>S.T.</given-names></name><name><surname>Cross</surname><given-names>D.A.E.</given-names></name><name><surname>Didelot</surname><given-names>M.</given-names></name><name><surname>Gavine</surname><given-names>P.R.</given-names></name><name><surname>Germain</surname><given-names>H.</given-names></name><name><surname>Harris</surname><given-names>C.S.</given-names></name><name><surname>Hughes</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Structure&#x02013;activity relationship of a series of non peptidic RGD integrin antagonists targeting &#x003b1;5&#x003b2;1: Part 2</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>22</volume><year>2012</year><fpage>4117</fpage><lpage>4121</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.04.061</pub-id><pub-id pub-id-type="pmid">22572578</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Haimbach</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Mayer-Ezell</surname><given-names>R.</given-names></name><name><surname>Garcia-Calvo</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>E.</given-names></name><name><surname>Price</surname><given-names>O.</given-names></name><name><surname>Kan</surname><given-names>Y.</given-names></name><name><surname>Zycband</surname><given-names>E.</given-names></name><etal/></person-group><article-title>An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model</article-title><source>Pharmacol. Res. Perspect.</source><volume>5</volume><year>2017</year><object-id pub-id-type="publisher-id">e00354</object-id><pub-id pub-id-type="doi">10.1002/prp2.354</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Camillo</surname><given-names>C.</given-names></name><name><surname>Facchinello</surname><given-names>N.</given-names></name><name><surname>Villari</surname><given-names>G.</given-names></name><name><surname>Mana</surname><given-names>G.</given-names></name><name><surname>Gioelli</surname><given-names>N.</given-names></name><name><surname>Sandri</surname><given-names>C.</given-names></name><name><surname>Astone</surname><given-names>M.</given-names></name><name><surname>Tortarolo</surname><given-names>D.</given-names></name><name><surname>Clapero</surname><given-names>F.</given-names></name><name><surname>Gays</surname><given-names>D.</given-names></name><etal/></person-group><article-title>LPHN2 inhibits vascular permeability by differential control of endothelial cell adhesion</article-title><source>J.&#x000a0;Cell Biol.</source><volume>220</volume><year>2021</year><object-id pub-id-type="publisher-id">e202006033</object-id><pub-id pub-id-type="doi">10.1083/jcb.202006033</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Srivastava</surname><given-names>N.</given-names></name><name><surname>Vikarunnessa</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.B.</given-names></name><name><surname>Jiang</surname><given-names>J.</given-names></name><name><surname>Cowan</surname><given-names>C.W.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization</article-title><source>Sci. Signal.</source><volume>5</volume><year>2012</year><object-id pub-id-type="publisher-id">ra6</object-id><pub-id pub-id-type="doi">10.1126/scisignal.2002636</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Pascoe</surname><given-names>H.G.</given-names></name><name><surname>Brautigam</surname><given-names>C.A.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name></person-group><article-title>Structural basis for activation and non-canonical catalysis of the Rap GTPase activating protein domain of plexin</article-title><source>Elife</source><volume>2</volume><year>2013</year><object-id pub-id-type="publisher-id">e01279</object-id><pub-id pub-id-type="doi">10.7554/eLife.01279</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Calderwood</surname><given-names>D.A.</given-names></name><name><surname>Campbell</surname><given-names>I.D.</given-names></name><name><surname>Critchley</surname><given-names>D.R.</given-names></name></person-group><article-title>Talins and kindlins: partners in integrin-mediated adhesion</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>14</volume><year>2013</year><fpage>503</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nrm3624</pub-id><pub-id pub-id-type="pmid">23860236</pub-id>
</element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Lagarrigue</surname><given-names>F.</given-names></name><name><surname>Ginsberg</surname><given-names>M.H.</given-names></name></person-group><article-title>The Connection Between Rap1 and Talin1 in the Activation of Integrins in Blood Cells</article-title><source>Front Cell Dev Biol</source><volume>10</volume><year>2022</year><object-id pub-id-type="publisher-id">908622</object-id><pub-id pub-id-type="doi">10.3389/fcell.2022.908622</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Atherton</surname><given-names>P.</given-names></name><name><surname>Konstantinou</surname><given-names>R.</given-names></name><name><surname>Neo</surname><given-names>S.P.</given-names></name><name><surname>Wang</surname><given-names>E.</given-names></name><name><surname>Balloi</surname><given-names>E.</given-names></name><name><surname>Ptushkina</surname><given-names>M.</given-names></name><name><surname>Bennett</surname><given-names>H.</given-names></name><name><surname>Clark</surname><given-names>K.</given-names></name><name><surname>Gunaratne</surname><given-names>J.</given-names></name><name><surname>Critchley</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Tensin3 interaction with talin drives the formation of fibronectin-associated fibrillar adhesions</article-title><source>J.&#x000a0;Cell Biol.</source><volume>221</volume><year>2022</year><object-id pub-id-type="publisher-id">e202107022</object-id><pub-id pub-id-type="doi">10.1083/jcb.202107022</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Obermajer</surname><given-names>N.</given-names></name><name><surname>Jevnikar</surname><given-names>Z.</given-names></name><name><surname>Doljak</surname><given-names>B.</given-names></name><name><surname>Sadaghiani</surname><given-names>A.M.</given-names></name><name><surname>Bogyo</surname><given-names>M.</given-names></name><name><surname>Kos</surname><given-names>J.</given-names></name></person-group><article-title>Cathepsin X-mediated &#x003b2;2 integrin activation results in nanotube outgrowth</article-title><source>Cell. Mol. Life Sci.</source><volume>66</volume><year>2009</year><fpage>1126</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1007/s00018-009-8829-8</pub-id><pub-id pub-id-type="pmid">19194656</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M.</given-names></name><name><surname>Jiang</surname><given-names>Y.Z.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Ell</surname><given-names>B.</given-names></name><name><surname>Sheng</surname><given-names>X.</given-names></name><name><surname>Esposito</surname><given-names>M.</given-names></name><name><surname>Kang</surname><given-names>J.</given-names></name><name><surname>Hang</surname><given-names>X.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name><name><surname>Rowicki</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling</article-title><source>Cancer Cell</source><volume>35</volume><year>2019</year><fpage>64</fpage><lpage>80.e7</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.11.016</pub-id><pub-id pub-id-type="pmid">30612941</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>F.</given-names></name><name><surname>Heesom</surname><given-names>K.J.</given-names></name><name><surname>Bass</surname><given-names>M.D.</given-names></name><name><surname>Cullen</surname><given-names>P.J.</given-names></name></person-group><article-title>SNX17 protects integrins from degradation by sorting between lysosomal and recycling pathways</article-title><source>J.&#x000a0;Cell Biol.</source><volume>197</volume><year>2012</year><fpage>219</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1083/jcb.201111121</pub-id><pub-id pub-id-type="pmid">22492727</pub-id>
</element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>A.</given-names></name><name><surname>Veltel</surname><given-names>S.</given-names></name><name><surname>Pellinen</surname><given-names>T.</given-names></name><name><surname>Padzik</surname><given-names>A.</given-names></name><name><surname>Coffey</surname><given-names>E.</given-names></name><name><surname>Marjom&#x000e4;ki</surname><given-names>V.</given-names></name><name><surname>Ivaska</surname><given-names>J.</given-names></name></person-group><article-title>Competitive binding of Rab21 and p120RasGAP to integrins regulates receptor traffic and migration</article-title><source>J.&#x000a0;Cell Biol.</source><volume>194</volume><year>2011</year><fpage>291</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1083/jcb.201012126</pub-id><pub-id pub-id-type="pmid">21768288</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Benwell</surname><given-names>C.J.</given-names></name><name><surname>Johnson</surname><given-names>R.T.</given-names></name><name><surname>Taylor</surname><given-names>J.A.G.E.</given-names></name><name><surname>Lambert</surname><given-names>J.</given-names></name><name><surname>Robinson</surname><given-names>S.D.</given-names></name></person-group><article-title>A proteomics approach to isolating neuropilin-dependent &#x003b1;5 integrin trafficking pathways: neuropilin 1 and 2 co-traffic &#x003b1;5 integrin through endosomal p120RasGAP to promote polarised fibronectin fibrillogenesis in endothelial cells</article-title><source>Commun. Biol.</source><volume>7</volume><year>2024</year><fpage>629</fpage><pub-id pub-id-type="doi">10.1038/s42003-024-06320-4</pub-id><pub-id pub-id-type="pmid">38789481</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Yoo</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>E.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name><name><surname>Guan</surname><given-names>J.-L.</given-names></name></person-group><article-title>Regulation of Integrin &#x003b2;1 Recycling to Lipid Rafts by Rab1a to Promote Cell Migration</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>285</volume><year>2010</year><fpage>29398</fpage><lpage>29405</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.141440</pub-id><pub-id pub-id-type="pmid">20639577</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>E.</given-names></name><name><surname>Leszczynska</surname><given-names>K.</given-names></name><name><surname>Poulter</surname><given-names>N.S.</given-names></name><name><surname>Edelmann</surname><given-names>F.</given-names></name><name><surname>Salisbury</surname><given-names>V.A.</given-names></name><name><surname>Noy</surname><given-names>P.J.</given-names></name><name><surname>Bacon</surname><given-names>A.</given-names></name><name><surname>Rappoport</surname><given-names>J.Z.</given-names></name><name><surname>Heath</surname><given-names>J.K.</given-names></name><name><surname>Bicknell</surname><given-names>R.</given-names></name><name><surname>Heath</surname><given-names>V.L.</given-names></name></person-group><article-title>RhoJ interacts with the GIT-PIX complex and regulates focal adhesion disassembly</article-title><source>J.&#x000a0;Cell Sci.</source><volume>127</volume><year>2014</year><fpage>3039</fpage><lpage>3051</lpage><pub-id pub-id-type="doi">10.1242/jcs.140434</pub-id><pub-id pub-id-type="pmid">24928894</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Centonze</surname><given-names>G.</given-names></name><name><surname>Natalini</surname><given-names>D.</given-names></name><name><surname>Salemme</surname><given-names>V.</given-names></name><name><surname>Costamagna</surname><given-names>A.</given-names></name><name><surname>Cabodi</surname><given-names>S.</given-names></name><name><surname>Defilippi</surname><given-names>P.</given-names></name></person-group><article-title>p130Cas/BCAR1 and p140Cap/SRCIN1 Adaptors: The Yin Yang in Breast Cancer?</article-title><source>Front. Cell Dev. Biol.</source><volume>9</volume><year>2021</year><object-id pub-id-type="publisher-id">729093</object-id><pub-id pub-id-type="doi">10.3389/fcell.2021.729093</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Hua</surname><given-names>Z.</given-names></name></person-group><article-title>The interaction of CFLAR with p130Cas promotes cell migration</article-title><source>Biochim. Biophys. Acta Mol. Cell Res.</source><volume>1870</volume><year>2023</year><object-id pub-id-type="publisher-id">119390</object-id><pub-id pub-id-type="doi">10.1016/j.bbamcr.2022.119390</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Babina</surname><given-names>I.S.</given-names></name><name><surname>Turner</surname><given-names>N.C.</given-names></name></person-group><article-title>Advances and challenges in targeting FGFR signalling in cancer</article-title><source>Nature Reviews Cancer</source><volume>17</volume><year>2017</year><fpage>318</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.8</pub-id><pub-id pub-id-type="pmid">28303906</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Byzova</surname><given-names>T.V.</given-names></name><name><surname>Goldman</surname><given-names>C.K.</given-names></name><name><surname>Pampori</surname><given-names>N.</given-names></name><name><surname>Thomas</surname><given-names>K.A.</given-names></name><name><surname>Bett</surname><given-names>A.</given-names></name><name><surname>Shattil</surname><given-names>S.J.</given-names></name><name><surname>Plow</surname><given-names>E.F.</given-names></name></person-group><article-title>A mechanism for modulation of cellular responses to VEGF: activation of the integrins</article-title><source>Mol. Cell</source><volume>6</volume><year>2000</year><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">11090623</pub-id>
</element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Su</surname><given-names>W.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Lv</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>P.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Ferbeyre</surname><given-names>G.</given-names></name><name><surname>Cao</surname><given-names>X.</given-names></name><name><surname>Wan</surname><given-names>M.</given-names></name></person-group><article-title>Osteoclasts protect bone blood vessels against senescence through the angiogenin/plexin-B2 axis</article-title><source>Nat. Commun.</source><volume>12</volume><year>2021</year><fpage>1832</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22131-1</pub-id><pub-id pub-id-type="pmid">33758201</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Basile</surname><given-names>J.R.</given-names></name><name><surname>Barac</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>T.</given-names></name><name><surname>Guan</surname><given-names>K.L.</given-names></name><name><surname>Gutkind</surname><given-names>J.S.</given-names></name></person-group><article-title>Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B</article-title><source>Cancer Res.</source><volume>64</volume><year>2004</year><fpage>5212</fpage><lpage>5224</lpage><pub-id pub-id-type="pmid">15289326</pub-id>
</element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Conrotto</surname><given-names>P.</given-names></name><name><surname>Valdembri</surname><given-names>D.</given-names></name><name><surname>Corso</surname><given-names>S.</given-names></name><name><surname>Serini</surname><given-names>G.</given-names></name><name><surname>Tamagnone</surname><given-names>L.</given-names></name><name><surname>Comoglio</surname><given-names>P.M.</given-names></name><name><surname>Bussolino</surname><given-names>F.</given-names></name><name><surname>Giordano</surname><given-names>S.</given-names></name></person-group><article-title>Sema4D induces angiogenesis through Met recruitment by Plexin B1</article-title><source>Blood</source><volume>105</volume><year>2005</year><fpage>4321</fpage><lpage>4329</lpage><pub-id pub-id-type="pmid">15632204</pub-id>
</element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Czekay</surname><given-names>R.P.</given-names></name><name><surname>Robillard</surname><given-names>L.</given-names></name><name><surname>Kugler</surname><given-names>M.C.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Kim</surname><given-names>K.K.</given-names></name><name><surname>Xiong</surname><given-names>J.P.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name><name><surname>Chapman</surname><given-names>H.A.</given-names></name></person-group><article-title>Regulation of &#x003b1;5&#x003b2;1 integrin conformation and function by urokinase receptor binding</article-title><source>J.&#x000a0;Cell Biol.</source><volume>168</volume><year>2005</year><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1083/jcb.200404112</pub-id><pub-id pub-id-type="pmid">15684035</pub-id>
</element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Jacquemet</surname><given-names>G.</given-names></name><name><surname>Morgan</surname><given-names>M.R.</given-names></name><name><surname>Byron</surname><given-names>A.</given-names></name><name><surname>Humphries</surname><given-names>J.D.</given-names></name><name><surname>Choi</surname><given-names>C.K.</given-names></name><name><surname>Chen</surname><given-names>C.S.</given-names></name><name><surname>Caswell</surname><given-names>P.T.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name></person-group><article-title>Rac1 is deactivated at integrin activation sites through an IQGAP1-filamin-A-RacGAP1 pathway</article-title><source>J.&#x000a0;Cell Sci.</source><volume>126</volume><year>2013</year><fpage>4121</fpage><lpage>4135</lpage><pub-id pub-id-type="doi">10.1242/jcs.121988</pub-id><pub-id pub-id-type="pmid">23843620</pub-id>
</element-citation></ref><ref id="bib64"><label>60</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Bry</surname><given-names>M.</given-names></name><name><surname>Kivel&#x000e4;</surname><given-names>R.</given-names></name><name><surname>Lepp&#x000e4;nen</surname><given-names>V.M.</given-names></name><name><surname>Alitalo</surname><given-names>K.</given-names></name></person-group><article-title>Vascular endothelial growth factor-B in physiology and disease</article-title><source>Physiol Rev</source><volume>94</volume><year>2013</year><fpage>779</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1152/physrev.00028.2013</pub-id></element-citation></ref><ref id="bib60"><label>61</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Lignitto</surname><given-names>L.</given-names></name><name><surname>Carlucci</surname><given-names>A.</given-names></name><name><surname>Sepe</surname><given-names>M.</given-names></name><name><surname>Stefan</surname><given-names>E.</given-names></name><name><surname>Cuomo</surname><given-names>O.</given-names></name><name><surname>Nistic&#x000f2;</surname><given-names>R.</given-names></name><name><surname>Scorziello</surname><given-names>A.</given-names></name><name><surname>Savoia</surname><given-names>C.</given-names></name><name><surname>Garbi</surname><given-names>C.</given-names></name><name><surname>Annunziato</surname><given-names>L.</given-names></name><name><surname>Feliciello</surname><given-names>A.</given-names></name></person-group><article-title>Control of PKA stability and signalling by the RING ligase praja2</article-title><source>Nat. Cell Biol.</source><volume>13</volume><year>2011</year><fpage>412</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/ncb2209</pub-id><pub-id pub-id-type="pmid">21423175</pub-id>
</element-citation></ref><ref id="bib61"><label>62</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M.</given-names></name><name><surname>Otani</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Goult</surname><given-names>B.T.</given-names></name><name><surname>Howe</surname><given-names>A.K.</given-names></name></person-group><article-title>The focal adhesion protein talin is a mechanically gated A-kinase anchoring protein</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>121</volume><year>2024</year><object-id pub-id-type="publisher-id">e2314947121</object-id><pub-id pub-id-type="doi">10.1073/pnas.2314947121</pub-id></element-citation></ref><ref id="bib62"><label>63</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chi</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Kindlin-2 Inhibits the Hippo Signaling Pathway by Promoting Degradation of MOB1</article-title><source>Cell Rep.</source><volume>29</volume><year>2019</year><fpage>3664</fpage><lpage>3677.e5</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.11.035</pub-id><pub-id pub-id-type="pmid">31825843</pub-id>
</element-citation></ref><ref id="bib63"><label>64</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Lignitto</surname><given-names>L.</given-names></name><name><surname>Arcella</surname><given-names>A.</given-names></name><name><surname>Sepe</surname><given-names>M.</given-names></name><name><surname>Rinaldi</surname><given-names>L.</given-names></name><name><surname>Delle Donne</surname><given-names>R.</given-names></name><name><surname>Gallo</surname><given-names>A.</given-names></name><name><surname>Stefan</surname><given-names>E.</given-names></name><name><surname>Bachmann</surname><given-names>V.A.</given-names></name><name><surname>Oliva</surname><given-names>M.A.</given-names></name><name><surname>Tiziana Storlazzi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Proteolysis of MOB1 by the ubiquitin ligase praja2 attenuates Hippo signalling and supports glioblastoma growth</article-title><source>Nat. Commun.</source><volume>4</volume><year>2013</year><fpage>1822</fpage><pub-id pub-id-type="doi">10.1038/ncomms2791</pub-id><pub-id pub-id-type="pmid">23652010</pub-id>
</element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Hosaka</surname><given-names>K.</given-names></name><name><surname>Andersson</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Tholander</surname><given-names>F.</given-names></name><name><surname>Cao</surname><given-names>Z.</given-names></name><name><surname>Morikawa</surname><given-names>H.</given-names></name><name><surname>Tegn&#x000e9;r</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>VEGF-B promotes cancer metastasis through a VEGF-A-independent mechanism and serves as a marker of poor prognosis for cancer patients</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>112</volume><year>2015</year><fpage>E2900</fpage><lpage>E2909</lpage><pub-id pub-id-type="doi">10.1073/pnas.1503500112</pub-id><pub-id pub-id-type="pmid">25991856</pub-id>
</element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>C.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Jensen</surname><given-names>L.D.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><etal/></person-group><article-title>VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway</article-title><source>Signal Transduct. Targeted Ther.</source><volume>8</volume><year>2023</year><fpage>305</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01539-9</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Albrecht</surname><given-names>I.</given-names></name><name><surname>Kopfstein</surname><given-names>L.</given-names></name><name><surname>Strittmatter</surname><given-names>K.</given-names></name><name><surname>Schomber</surname><given-names>T.</given-names></name><name><surname>Falkevall</surname><given-names>A.</given-names></name><name><surname>Hagberg</surname><given-names>C.E.</given-names></name><name><surname>Lorentz</surname><given-names>P.</given-names></name><name><surname>Jeltsch</surname><given-names>M.</given-names></name><name><surname>Alitalo</surname><given-names>K.</given-names></name><name><surname>Eriksson</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Suppressive Effects of Vascular Endothelial Growth Factor-B on Tumor Growth in a Mouse Model of Pancreatic Neuroendocrine Tumorigenesis</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><object-id pub-id-type="publisher-id">e14109</object-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Lilja</surname><given-names>J.</given-names></name><name><surname>Zacharchenko</surname><given-names>T.</given-names></name><name><surname>Georgiadou</surname><given-names>M.</given-names></name><name><surname>Jacquemet</surname><given-names>G.</given-names></name><name><surname>De Franceschi</surname><given-names>N.</given-names></name><name><surname>Peuhu</surname><given-names>E.</given-names></name><name><surname>Hamidi</surname><given-names>H.</given-names></name><name><surname>Pouwels</surname><given-names>J.</given-names></name><name><surname>Martens</surname><given-names>V.</given-names></name><name><surname>Nia</surname><given-names>F.H.</given-names></name><etal/></person-group><article-title>SHANK proteins limit integrin activation by directly interacting with Rap1 and R-Ras</article-title><source>Nat. Cell Biol.</source><volume>19</volume><year>2017</year><fpage>292</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/ncb3487</pub-id><pub-id pub-id-type="pmid">28263956</pub-id>
</element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Villari</surname><given-names>G.</given-names></name><name><surname>Gioelli</surname><given-names>N.</given-names></name><name><surname>Valdembri</surname><given-names>D.</given-names></name><name><surname>Serini</surname><given-names>G.</given-names></name></person-group><article-title>Vesicle choreographies keep up cell-to-extracellular matrix adhesion dynamics in polarized epithelial and endothelial cells</article-title><source>Matrix Biol.</source><volume>112</volume><year>2022</year><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.matbio.2022.08.003</pub-id><pub-id pub-id-type="pmid">35961423</pub-id>
</element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Noordstra</surname><given-names>I.</given-names></name><name><surname>van den Berg</surname><given-names>C.M.</given-names></name><name><surname>Boot</surname><given-names>F.W.J.</given-names></name><name><surname>Katrukha</surname><given-names>E.A.</given-names></name><name><surname>Yu</surname><given-names>K.L.</given-names></name><name><surname>Tas</surname><given-names>R.P.</given-names></name><name><surname>Portegies</surname><given-names>S.</given-names></name><name><surname>Viergever</surname><given-names>B.J.</given-names></name><name><surname>de Graaff</surname><given-names>E.</given-names></name><name><surname>Hoogenraad</surname><given-names>C.C.</given-names></name><etal/></person-group><article-title>Organization and dynamics of the cortical complexes controlling insulin secretion in &#x003b2;-cells</article-title><source>J.&#x000a0;Cell Sci.</source><volume>135</volume><year>2022</year><object-id pub-id-type="publisher-id">jcs259430</object-id><pub-id pub-id-type="doi">10.1242/jcs.259430</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Z.</given-names></name><name><surname>Tseng</surname><given-names>H.Y.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Senger</surname><given-names>F.</given-names></name><name><surname>Kurzawa</surname><given-names>L.</given-names></name><name><surname>Dedden</surname><given-names>D.</given-names></name><name><surname>Mizuno</surname><given-names>N.</given-names></name><name><surname>Wasik</surname><given-names>A.A.</given-names></name><name><surname>Thery</surname><given-names>M.</given-names></name><name><surname>Dunn</surname><given-names>A.R.</given-names></name><name><surname>F&#x000e4;ssler</surname><given-names>R.</given-names></name></person-group><article-title>Kank2 activates talin, reduces force transduction across integrins and induces central adhesion formation</article-title><source>Nat. Cell Biol.</source><volume>18</volume><year>2016</year><fpage>941</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1038/ncb3402</pub-id><pub-id pub-id-type="pmid">27548916</pub-id>
</element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Stephanie</surname><given-names>S.</given-names></name><name><surname>Dirk</surname><given-names>D.</given-names></name><name><surname>Vazquez</surname><given-names>N.R.</given-names></name><name><surname>Kyoko</surname><given-names>M.</given-names></name><name><surname>Christian</surname><given-names>B.</given-names></name><name><surname>Junichi</surname><given-names>T.</given-names></name><name><surname>Naoko</surname><given-names>M.</given-names></name></person-group><article-title>Structural insights into integrin &#x003b1;5&#x003b2;1 opening by fibronectin ligand</article-title><source>Sci. Adv.</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">eabe9716</object-id><pub-id pub-id-type="doi">10.1126/sciadv.abe9716</pub-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Walz</surname><given-names>T.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name><name><surname>Vestweber</surname><given-names>D.</given-names></name><name><surname>Caba&#x000f1;as</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Springer</surname><given-names>T.A.</given-names></name></person-group><article-title>Relating conformation to function in integrin &#x003b1;5&#x003b2;1</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>113</volume><year>2016</year><fpage>E3872</fpage><lpage>E3881</lpage><pub-id pub-id-type="doi">10.1073/pnas.1605074113</pub-id><pub-id pub-id-type="pmid">27317747</pub-id>
</element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>W.</given-names></name><name><surname>Qin</surname><given-names>Y.</given-names></name><name><surname>Humphries</surname><given-names>M.J.</given-names></name><name><surname>Vestweber</surname><given-names>D.</given-names></name><name><surname>Caba&#x000f1;as</surname><given-names>C.</given-names></name><name><surname>Lu</surname><given-names>C.</given-names></name><name><surname>Springer</surname><given-names>T.A.</given-names></name></person-group><article-title>Conformational equilibria and intrinsic affinities define integrin activation</article-title><source>EMBO J.</source><volume>36</volume><year>2017</year><fpage>629</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.15252/embj.201695803</pub-id><pub-id pub-id-type="pmid">28122868</pub-id>
</element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Serini</surname><given-names>G.</given-names></name><name><surname>Valdembri</surname><given-names>D.</given-names></name><name><surname>Zanivan</surname><given-names>S.</given-names></name><name><surname>Morterra</surname><given-names>G.</given-names></name><name><surname>Burkhardt</surname><given-names>C.</given-names></name><name><surname>Caccavari</surname><given-names>F.</given-names></name><name><surname>Zammataro</surname><given-names>L.</given-names></name><name><surname>Primo</surname><given-names>L.</given-names></name><name><surname>Tamagnone</surname><given-names>L.</given-names></name><name><surname>Logan</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function</article-title><source>Nature</source><volume>424</volume><year>2003</year><fpage>391</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">12879061</pub-id>
</element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Serini</surname><given-names>G.</given-names></name><name><surname>Bussolino</surname><given-names>F.</given-names></name></person-group><article-title>Common cues in vascular and axon guidance</article-title><source>Physiology</source><volume>19</volume><year>2004</year><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">15546852</pub-id>
</element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Bouvard</surname><given-names>D.</given-names></name><name><surname>Pouwels</surname><given-names>J.</given-names></name><name><surname>De Franceschi</surname><given-names>N.</given-names></name><name><surname>Ivaska</surname><given-names>J.</given-names></name></person-group><article-title>Integrin inactivators: balancing cellular functions in&#x000a0;vitro and in&#x000a0;vivo</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>14</volume><year>2013</year><fpage>430</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nrm3599</pub-id><pub-id pub-id-type="pmid">23719537</pub-id>
</element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Krcmery</surname><given-names>J.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Sadleir</surname><given-names>R.W.</given-names></name><name><surname>Ahrens</surname><given-names>M.J.</given-names></name><name><surname>Misener</surname><given-names>S.</given-names></name><name><surname>Kamide</surname><given-names>C.</given-names></name><name><surname>Fitchev</surname><given-names>P.</given-names></name><name><surname>Losordo</surname><given-names>D.W.</given-names></name><name><surname>Crawford</surname><given-names>S.E.</given-names></name><name><surname>Simon</surname><given-names>H.-G.</given-names></name></person-group><article-title>Loss of the Cytoskeletal Protein Pdlim7 Predisposes Mice to Heart Defects and Hemostatic Dysfunction</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e80809</object-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Janus-Bell</surname><given-names>E.</given-names></name><name><surname>Mangin</surname><given-names>P.H.</given-names></name></person-group><article-title>The relative importance of platelet integrins in hemostasis, thrombosis and beyond</article-title><source>Haematologica</source><volume>108</volume><year>2023</year><fpage>1734</fpage><lpage>1747</lpage><pub-id pub-id-type="doi">10.3324/haematol.2022.282136</pub-id><pub-id pub-id-type="pmid">36700400</pub-id>
</element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S.</given-names></name><name><surname>Braun</surname><given-names>A.</given-names></name><name><surname>Morowski</surname><given-names>M.</given-names></name><name><surname>Premsler</surname><given-names>T.</given-names></name><name><surname>Bender</surname><given-names>M.</given-names></name><name><surname>Nagy</surname><given-names>Z.</given-names></name><name><surname>Sickmann</surname><given-names>A.</given-names></name><name><surname>Hermanns</surname><given-names>H.M.</given-names></name><name><surname>B&#x000f6;sl</surname><given-names>M.</given-names></name><name><surname>Nieswandt</surname><given-names>B.</given-names></name></person-group><article-title>CLP36 Is a Negative Regulator of Glycoprotein VI Signaling in Platelets</article-title><source>Circ. Res.</source><volume>111</volume><year>2012</year><fpage>1410</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.112.264754</pub-id><pub-id pub-id-type="pmid">22955732</pub-id>
</element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Perike</surname><given-names>S.</given-names></name><name><surname>Gonzalez-Gonzalez</surname><given-names>F.J.</given-names></name><name><surname>Abu-Taha</surname><given-names>I.</given-names></name><name><surname>Damen</surname><given-names>F.W.</given-names></name><name><surname>Hanft</surname><given-names>L.M.</given-names></name><name><surname>Lizama</surname><given-names>K.S.</given-names></name><name><surname>Aboonabi</surname><given-names>A.</given-names></name><name><surname>Capote</surname><given-names>A.E.</given-names></name><name><surname>Aguilar-Sanchez</surname><given-names>Y.</given-names></name><name><surname>Levin</surname><given-names>B.</given-names></name><etal/></person-group><article-title>PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation</article-title><source>Circ. Res.</source><volume>133</volume><year>2023</year><fpage>758</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.123.322516</pub-id><pub-id pub-id-type="pmid">37737016</pub-id>
</element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Vicente-Manzanares</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Adelstein</surname><given-names>R.S.</given-names></name><name><surname>Horwitz</surname><given-names>A.R.</given-names></name></person-group><article-title>Non-muscle myosin II takes centre stage in cell adhesion and migration</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>10</volume><year>2009</year><fpage>778</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1038/nrm2786</pub-id><pub-id pub-id-type="pmid">19851336</pub-id>
</element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Posor</surname><given-names>Y.</given-names></name><name><surname>Jang</surname><given-names>W.</given-names></name><name><surname>Haucke</surname><given-names>V.</given-names></name></person-group><article-title>Phosphoinositides as membrane organizers</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>23</volume><year>2022</year><fpage>797</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1038/s41580-022-00490-x</pub-id><pub-id pub-id-type="pmid">35589852</pub-id>
</element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>Y.I.</given-names></name><name><surname>Spano</surname><given-names>M.M.</given-names></name><name><surname>Gumbiner</surname><given-names>B.M.</given-names></name></person-group><article-title>Conformational epitopes at cadherin calcium-binding sites and p120-catenin phosphorylation regulate cell adhesion</article-title><source>Mol. Biol. Cell</source><volume>23</volume><year>2012</year><fpage>2092</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1091/mbc.E11-12-1060</pub-id><pub-id pub-id-type="pmid">22513089</pub-id>
</element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Shashikanth</surname><given-names>N.</given-names></name><name><surname>Petrova</surname><given-names>Y.I.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Chekan</surname><given-names>J.</given-names></name><name><surname>Maiden</surname><given-names>S.</given-names></name><name><surname>Spano</surname><given-names>M.</given-names></name><name><surname>Ha</surname><given-names>T.</given-names></name><name><surname>Gumbiner</surname><given-names>B.M.</given-names></name><name><surname>Leckband</surname><given-names>D.E.</given-names></name></person-group><article-title>Allosteric Regulation of E-Cadherin Adhesion</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>290</volume><year>2015</year><fpage>21749</fpage><lpage>21761</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.657098</pub-id><pub-id pub-id-type="pmid">26175155</pub-id>
</element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>Na</surname><given-names>T.-Y.</given-names></name><name><surname>Schecterson</surname><given-names>L.</given-names></name><name><surname>Mendonsa</surname><given-names>A.M.</given-names></name><name><surname>Gumbiner</surname><given-names>B.M.</given-names></name></person-group><article-title>The functional activity of E-cadherin controls tumor cell metastasis at multiple steps</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>117</volume><year>2020</year><fpage>5931</fpage><lpage>5937</lpage><pub-id pub-id-type="doi">10.1073/pnas.1918167117</pub-id><pub-id pub-id-type="pmid">32127478</pub-id>
</element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Koirala</surname><given-names>R.</given-names></name><name><surname>Priest</surname><given-names>A.V.</given-names></name><name><surname>Yen</surname><given-names>C.-F.</given-names></name><name><surname>Cheah</surname><given-names>J.S.</given-names></name><name><surname>Pannekoek</surname><given-names>W.-J.</given-names></name><name><surname>Gloerich</surname><given-names>M.</given-names></name><name><surname>Yamada</surname><given-names>S.</given-names></name><name><surname>Sivasankar</surname><given-names>S.</given-names></name></person-group><article-title>Inside-out regulation of E-cadherin conformation and adhesion</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>118</volume><year>2021</year><object-id pub-id-type="publisher-id">e2104090118</object-id><pub-id pub-id-type="doi">10.1073/pnas.2104090118</pub-id></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Y.</given-names></name><name><surname>Janssen</surname><given-names>B.J.C.</given-names></name><name><surname>Malinauskas</surname><given-names>T.</given-names></name><name><surname>Vangoor</surname><given-names>V.R.</given-names></name><name><surname>Coles</surname><given-names>C.H.</given-names></name><name><surname>Kaufmann</surname><given-names>R.</given-names></name><name><surname>Ni</surname><given-names>T.</given-names></name><name><surname>Gilbert</surname><given-names>R.J.C.</given-names></name><name><surname>Padilla-Parra</surname><given-names>S.</given-names></name><name><surname>Pasterkamp</surname><given-names>R.J.</given-names></name><name><surname>Jones</surname><given-names>E.Y.</given-names></name></person-group><article-title>Structural Basis for Plexin Activation and Regulation</article-title><source>Neuron</source><volume>91</volume><year>2016</year><fpage>548</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.06.018</pub-id><pub-id pub-id-type="pmid">27397516</pub-id>
</element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Beglova</surname><given-names>N.</given-names></name><name><surname>Jeon</surname><given-names>H.</given-names></name><name><surname>Fisher</surname><given-names>C.</given-names></name><name><surname>Blacklow</surname><given-names>S.C.</given-names></name></person-group><article-title>Cooperation between Fixed and Low pH-Inducible Interfaces Controls Lipoprotein Release by the LDL Receptor</article-title><source>Mol. Cell</source><volume>16</volume><year>2004</year><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.09.038</pub-id><pub-id pub-id-type="pmid">15494314</pub-id>
</element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Beglova</surname><given-names>N.</given-names></name><name><surname>Blacklow</surname><given-names>S.C.</given-names></name></person-group><article-title>The LDL receptor: how acid pulls the trigger</article-title><source>Trends Biochem. Sci.</source><volume>30</volume><year>2005</year><fpage>309</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2005.03.007</pub-id><pub-id pub-id-type="pmid">15950875</pub-id>
</element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>E.</given-names></name><name><surname>Zorn</surname><given-names>J.A.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Barros</surname><given-names>T.</given-names></name><name><surname>Kuriyan</surname><given-names>J.</given-names></name></person-group><article-title>A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor</article-title><source>Annu. Rev. Biochem.</source><volume>84</volume><year>2015</year><fpage>739</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-060614-034402</pub-id><pub-id pub-id-type="pmid">25621509</pub-id>
</element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Vizca&#x000ed;no</surname><given-names>J.A.</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>R.G.</given-names></name><name><surname>Csordas</surname><given-names>A.</given-names></name><name><surname>Dianes</surname><given-names>J.A.</given-names></name><name><surname>Fabregat</surname><given-names>A.</given-names></name><name><surname>Foster</surname><given-names>J.M.</given-names></name><name><surname>Griss</surname><given-names>J.</given-names></name><name><surname>Alpi</surname><given-names>E.</given-names></name><name><surname>Birim</surname><given-names>M.</given-names></name><name><surname>Contell</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>D1063</fpage><lpage>D1069</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1262</pub-id><pub-id pub-id-type="pmid">23203882</pub-id>
</element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Rehman</surname><given-names>M.</given-names></name><name><surname>Gurrapu</surname><given-names>S.</given-names></name><name><surname>Cagnoni</surname><given-names>G.</given-names></name><name><surname>Capparuccia</surname><given-names>L.</given-names></name><name><surname>Tamagnone</surname><given-names>L.</given-names></name></person-group><article-title>PlexinD1 Is a Novel Transcriptional Target and Effector of Notch Signaling in Cancer Cells</article-title><source>PLoS One</source><volume>11</volume><year>2016</year><object-id pub-id-type="publisher-id">e0164660</object-id><pub-id pub-id-type="doi">10.1371/journal.pone.0164660</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</article-title><source>Nat. Biotechnol.</source><volume>26</volume><year>2008</year><fpage>1367</fpage><lpage>1372</lpage><pub-id pub-id-type="doi">10.1038/nbt.1511</pub-id><pub-id pub-id-type="pmid">19029910</pub-id>
</element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>J.</given-names></name><name><surname>Neuhauser</surname><given-names>N.</given-names></name><name><surname>Michalski</surname><given-names>A.</given-names></name><name><surname>Scheltema</surname><given-names>R.A.</given-names></name><name><surname>Olsen</surname><given-names>J.V.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name></person-group><article-title>Andromeda: a peptide search engine integrated into the MaxQuant environment</article-title><source>J.&#x000a0;Proteome Res.</source><volume>10</volume><year>2011</year><fpage>1794</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1021/pr101065j</pub-id><pub-id pub-id-type="pmid">21254760</pub-id>
</element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Tyanova</surname><given-names>S.</given-names></name><name><surname>Temu</surname><given-names>T.</given-names></name><name><surname>Sinitcyn</surname><given-names>P.</given-names></name><name><surname>Carlson</surname><given-names>A.</given-names></name><name><surname>Hein</surname><given-names>M.Y.</given-names></name><name><surname>Geiger</surname><given-names>T.</given-names></name><name><surname>Mann</surname><given-names>M.</given-names></name><name><surname>Cox</surname><given-names>J.</given-names></name></person-group><article-title>The Perseus computational platform for comprehensive analysis of (prote)omics data</article-title><source>Nat. Methods</source><volume>13</volume><year>2016</year><fpage>731</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3901</pub-id><pub-id pub-id-type="pmid">27348712</pub-id>
</element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Hornbeck</surname><given-names>P.V.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Murray</surname><given-names>B.</given-names></name><name><surname>Kornhauser</surname><given-names>J.M.</given-names></name><name><surname>Latham</surname><given-names>V.</given-names></name><name><surname>Skrzypek</surname><given-names>E.</given-names></name></person-group><article-title>PhosphoSitePlus, 2014: mutations, PTMs and recalibrations</article-title><source>Nucleic Acids Res.</source><volume>43</volume><year>2015</year><fpage>D512</fpage><lpage>D520</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1267</pub-id><pub-id pub-id-type="pmid">25514926</pub-id>
</element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental information</title><p id="p0335">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures&#x000a0;S1&#x02013;S4</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Table&#x000a0;S1. <italic>p</italic> values for ANOVA comparisons</title></caption><media xlink:href="mmc2.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc3"><caption><title>Table&#x000a0;S2. HTS significant pathways</title></caption><media xlink:href="mmc3.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc4"><caption><title>Table&#x000a0;S3. MS proteomics analysis data</title></caption><media xlink:href="mmc4.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc5"><caption><title>Document S2. Article plus supplemental information</title></caption><media xlink:href="mmc5.pdf"/></supplementary-material>
</p></sec><fn-group><fn id="app1" fn-type="supplementary-material"><p id="p0330">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.celrep.2025.115319" id="intref0065">https://doi.org/10.1016/j.celrep.2025.115319</ext-link>.</p></fn></fn-group></back></article>